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DISTRIBUTION AND THE METABOLIC COMPLICATIONS OF 
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More than three-quarters (77%) of the 40.5 million people living in South Africa are 
black African, of which more than 40% are urbanised 1.  Black African women living in 
urban areas have a significantly higher prevalence (62%) of overweight than urban 
black males (28%) or white females (53%, 2).  It was previously thought that obesity in 
black South African women was not associated with deleterious metabolic sequelae 
and was termed “healthy” obesity 3. However, this is not the case as obese black 
women have double the diabetes (7.0 vs. 3.6%, 4,5) and hypertension (30 vs. 15%, 6) 
prevalence rates of obese white women, whereas obese white women more commonly 
present with coronary heart disease and hypercholesterolaemia 7.   
 
Interestingly, in small samples of obese women studied in South Africa, obese black 
women are more insulin resistant and have greater rates of lipolysis than obese white 
women 8-10.  This is surprising as black women have significantly less visceral adipose 
tissue than white women (~72 vs. 140 mm2 11,12).  These findings are similar to those in 
African America women.  Lovejoy et al. 13 found that African American women are 
more insulin resistant than Caucasian women, despite the fact that the African 
American women also have less visceral adipose tissue.  Insulin resistance in these 
women is associated with hyperinsulinaemia 13, which is in contrast to the findings in 
obese black South African women who more commonly present with relative 
insulinopaenia 8,14-16.  However, no direct assessment of insulin secretion in relation to 
the degree of insulin sensitivity has been performed in these women, which may lead 
to erroneous conclusions 17.  Determination of this relationship will increase our 
understanding of the underlying mechanisms contributing to the insulin resistance in 
these women, leading to more appropriate management or treatment.  
 
Visceral adipose tissue is strongly associated with insulin resistance, hypertension, 
dyslipidaemias amongst other factors, which contribute to an increased risk of coronary 
heart disease 18.  However, more recently the importance of subcutaneous adipose 
tissue as a significant determinant of insulin resistance has been recognised 19-22.  
When partitioning subcutaneous adipose tissue into superficial and deep 
compartments, Kelley et al. 20 found that deep subcutaneous adipose tissue showed as 
strong a relationship with insulin resistance as visceral adipose tissue (R=0.64 and 
R=0.61, respectively, both P<0.001), but there was no association between superficial 
subcutaneous adipose tissue and insulin sensitivity (R = -0.29, NS).  This finding may 
be important in explaining the higher prevalence of insulin resistance in obese black 
South African women who have relatively low levels of visceral adipose tissue, but high 
levels of subcutaneous adipose tissue compared to obese white women.   
 
One of the factors that may underlie the association between regional fat distribution 
and morbid sequelae may be exposure to glucocorticoids.  A case in point is the 
pathological condition of cortisol excess, Cushings syndrome, which is characterised 
by central obesity, hypertension, glucose intolerance and insulin resistance 23.  Studies 
examining changes in activity of the hypothalamic-pituitary-adrenal (HPA) axis with 
obesity have found that circulating levels of cortisol are normal, or even low 24-27.  
However, obese women, particularly those with visceral fat accumulation have elevated 
cortisol metabolic clearance rates, partly explained by increased urinary cortisol 
excretion 28,29, as well as hyperactivity of the HPA axis, characterised by elevated 
ACTH and cortisol secretion in response to CRF administration 28-31.  The increased 
sensitivity of the HPA axis in obesity, particularly central obesity measured by the 
waist:hip ratio, may be due, at least in part, to a reduction in the inhibitory feedback 
action of glucocorticoids on the HPA axis, as indicated by low-dose dexamethasone 
suppression tests 25 or 24-hr low-dose hydrocortisone infusions 27.  A single study 











30 Caucasian age- and weight-matched women, revealed only exaggerated plasma 
ACTH responses to CRH stimulation in the African America women 32.   
 
Recent studies suggest that glucocorticoid action on target tissues depends not only on 
the circulating concentrations, but also on the tissue sensitivity to glucocorticoids, 
which is determined by the levels of expression of glucocorticoid receptor isoforms 
(Gr  and GRß -  a dominant negative splicing variant present in variable amounts in 
some tissues) and 11ß-hydroxysteroid dehydrogenase type 1 (11 ß-HSD1).  11ß-HSD1 
is a NADP(H)-dependent reductase enzyme that reactivates cortisone to active cortisol 
in specific cells 33-38.  Obesity is associated with reduced activity of 11ß-HSD1 in liver, 
which may also explain the increased metabolic clearance rate of cortisone in patients 
with obesity 35,39.  In contrast, 11ß-HSD1 activity in adipose tissue is positively 
correlated with BMI 39,40.  It therefore appears that obesity is associated with tissue-
specific amplification of cortisol action, determined in part by increased expression of 
11ß-HSD1, in combination with increased glucocorticoid secretion.  These effects may 
be further exacerbated under stress, for example, urbanisation.   
 
Increased exposure of adipocytes to glucocorticoids may play a crucial role in 
adipocyte differentiation and the development of hypertension via its effects on the 
local renin-angiotensin system 41. Expression of angiotensinogen and angiotensin II is 
increased in adipose tissue, especially visceral adipose tissue, in obese 42 and obese 
hypertensive subjects 43.   Angiotensin II plays a dual role in regulating blood pressure 
and stimulating the production and release of prostacyclin, which promotes 
differentiation of precursor cells into adipocytes 44.  Recently, Masuzaki et al. 45 found 
that angiotensinogen expression is increased in transgenic mice that over-express 
11ßHSD1 selectively in adipose tissue and present with visceral obesity, hypertension 
and insulin-resistant diabetes (personal communication, JR Seckl).   
 
11ßHSD1 expression in human adipose tissue is up-regulated by TNF  46, a 
proinflammatory cytokine that is expressed in adipose tissue in proportion to the 
degree of adiposity 47.  TNF  has been implicated as a causative factor in obesity-
associated insulin resistance via its proposed effects on lipolysis, insulin-mediated 
signalling pathways, GLUT4 and PPAR  48.  More recently, other proteins released 
from adipose tissue have also been implicated as potential mediators of obesity-
associated insulin resistance.  Adiponectin, which is exclusively expressed in adipose 
tissue and is reduced in obesity 49, is positively associated with whole-body insulin 
sensitivity, independent of adiposity 50,51.  Conversely, the adipocyte-derived protein, 
resistin, may impair insulin action and glucose tolerance 52.  PPAR  plays a key 
facilitatory role in altering glucose metabolism by up-regulating adiponectin expression 
53 and down-regulating resistin expression 52.  Leptin appears to exert a hypoglycaemic 
action, which is partly independent of its effects on body composition 54.  Although 
these adipocyte-derived proteins have been implicated as causative factors in obesity-
associated insulin resistance in murine models, their relative importance in human 
models is less clear.  However, it does appear that each factor has distinct properties 
that may contribute differentially to obesity-associated insulin resistance.  
 
Although numerous studies have documented differences in body fat distribution 
between black and white South African women, there are no studies that have explored 
the possibility that the specific body fat distribution of black women, which was once 
considered to be “healthy”, is in fact the factor that predisposes them to hypertension 
and diabetes.  We therefore propose that it is indeed the differences in body fat 
distribution, which are associated with alterations in the regulation of the HPA axis, 











predispose these women to diabetes and hypertension, despite relatively low levels of 




Urbanised black South African women display a specific obesity phenotype, 
characterised by increased volume of deep subcutaneous adipose tissue.  This 
adipose tissue has increased expression of 11ß-HSD1 and/or glucocorticoid receptors 
and secondarily, altered local expression of key adipose receptors/mediators such as 
PPAR , angiotensinogen, leptin, TNF , adiponectin and resistin.  These mediators act 
to exacerbate the local and systemic obesity phenotype, also perhaps altering 
hypothalamic-pituitary-adrenal (HPA) axis feedback and activation, and thereby, 




The objectives of the study are to investigate differences between lean and obese 
black and white South African women, with specific reference to: 
i) The magnitude of deep vs. superficial subcutaneous vs. visceral adipose 
tissue; 
ii) The degree of insulin secretion in relation to insulin resistance;  
iii) The activity and regulation of the HPA axis; 
iv) The expression of 11ßHSD-1, glucocorticoid receptor isoforms, PPAR , 
angiotensinogen, leptin, TNF , adiponectin and resistin in visceral adipose 
tissue vs. deep vs. superficial subcutaneous abdominal adipose tissue vs. 
gluteal adipose tissue; 
v) The lipolytic activity of adipocytes from the different adipose tissue 
compartments to various physiological stimuli.  
 
The findings of this research can be used to highlight specific areas for intervention in 
terms of pharmacotherapy for the treatment of the co-morbid conditions associated 









Eighty urbanised, English-speaking black and white South African women between the 
ages of 21 and 45 years, matched for level of education, will be recruited for the study.  
Subjects will be excluded from the trial on the basis of the following criteria: i) receiving 
treatment for HIV/AIDS; ii) having any overt endocrine abnormality (e.g. diabetes 
mellitus); iii) undergoing endocrine therapy (e.g. oral corticosteroids, combined 
contraceptive pill); iv) currently pregnant or lactating; v) having hypertension or taking 
anti-hypertensive medications; vi) having polycystic ovarian syndrome; vii) having 
irregular menstrual cycles, viii) having less than a standard 8 (grade 10) education.  All 
















Subjects will be selected according to the following criteria: 
 
 Black White 
Normal weight – BMI < 25 kg/m2 20 20 
Obese - BMI > 30 kg/m2 20 20 
Total subjects 40 40 
 
Refer to Addendum for sample size determinations.  
 
Preliminary testing:   
 
Prior to participating in the trial, subjects will undergo preliminary testing to verify that 
they meet the inclusion criteria.  Blood pressure will be measured and glucose 
tolerance determined.  If subjects are found to be hypertensive (140/90 mmHg) and/or 
diabetic (according to the WHO criteria), they will be excluded from participating in the 
trial.  In addition, HIV screening will be performed and those who test positive for HIV 
infection will be excluded from the trial as HIV-1 infection is associated with 
abnormalities in HPA axis activity 55, lipodystrophy and insulin resistance, particularly in 
patients treated with HIV-1 protease inhibitors 56.  . 
 
i)   Blood pressure measurements: 
 
Blood pressure will be measured 3 times at 1-min intervals in each subject using an 
appropriately sized cuff and an Omron automated blood pressure monitor.  These 
measurements were taken after at least 20 min of seated rest.  An average of the 
last 2 readings will be used in the analyses.  If the subjects’ blood pressure is found 
to be over 140/90 mmHg on three separate occasions, they will be excluded from 
taking part in the study.  
 
i)   Oral glucose tolerance tests: 
 
In the morning, after an overnight fast (10-12 hr), subjects will report to the 
laboratory at the Sports Science Institute.  An indwelling cannula will be inserted 
into an antecubital vein.  Venous blood samples will be drawn 15 min prior to and 
30, 60, 90 and 120 min after the subjects have ingested 75 g glucose in 250 ml 
water.  One aliquot will be placed into a tube containing potassium oxalate and 
sodium fluoride for the determination of plasma glucose concentrations.  The 
remaining aliquot will be placed into a tube containing lithium heparin for the 
subsequent determination of plasma insulin concentrations.  All samples will be kept 
on ice until centrifuged at 3200 g at 4  C for 10 min upon completion of the test.  
Plasma samples will then be stored at –20  C for subsequent analyses.  Plasma 
glucose concentrations will be determined using the Glucose Oxidase method 
(Glucose Analyser 2; Beckman Instruments, Fullerton, CA).  Plasma insulin 
concentrations will be determined using a non-specific insulin radioimmunoassay 
(Count-A-Coat Insulin, Diagnostic Products, Los Angeles, CA).   
 
ii)   HIV screening: 
 
On the day of the oral glucose tolerance test, subjects will donate a 5 ml blood 
sample for HIV testing. Subjects will receive counselling by a trained counsellor 
prior to the test and after the results are obtained, unless the subject chooses not to 
know the result.  Referral will be made to appropriate HIV clinics for those subjects 
















a. Basic anthropometric measurements will be completed, including weight, height, 
waist and hip circumference. 
 
b. Dual-photon x-ray absorptiometry (DEXA) will be used to accurately measure body 
composition, including body fatness and muscle mass 57.  
 
c. Computerised tomography (CT) will be used to assess regional body fat distribution, 
including, visceral and deep and superficial subcutaneous adipose tissue area.  
Deep vs. superficial subcutaneous fat will be separated at the level of the fascia 
superficialis 20,58.  Each CT image will be taken at 120kV with a scanning time of 2 
seconds at 200mA, and a slice thickness of 5mm.  Subjects will be scanned in the 
supine position with legs slightly flexed and arms raised above the head.  Scans 
will be performed in arrested expiration at the L4/L5 level of the vertebra. 
 
 
b. Insulin secretion and insulin sensitivity: 
 
Insulin secretion and insulin sensitivity will be measured using the intravenous 
glucose tolerance test and the euglycaemic hyperinsulinaemic clamp technique59, 
respectively.  In order to estimate insulin secretion in relation to insulin sensitivity, 
the two tests will be performed in a sequential manner on the same day (Botnia 
clamp), as described previously 60,61.  Lehto et al. 60 compared the Botnia clamp to 
the euglycaemic clamp without prior intravenous glucose infusion and found the 
two tests to correlate strongly (r=0.94, P=0.0001).   
 
After an overnight fast (10-12 hr), an indwelling cannula will be inserted into an 
antecubital vein of both arms.  Ten minutes after a fasting blood sample is drawn, 
0.3 g/kg body weight of a 50 % glucose solution will be administered intravenously 
(time 0).  After 60 min, an infusion (infusion rate of 45 mU/m2) of short-acting 
human insulin (Actrapid, Novo Nordisk) will be started and continued until 180 min.  
A 20 % glucose solution will be infused at a variable rate to maintain blood glucose 
concentrations unchanged at 5.5 mmol/l.  Blood samples (5 ml) will be drawn from 
the opposite arm at –10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60 min for the 
determination of blood glucose and insulin concentrations.  Thereafter, blood 
samples will be obtained at 5-min intervals throughout the euglycaemic clamp for 
the determination of blood glucose concentrations and at 120, 170 and 180 min for 
the subsequent determination of plasma insulin concentrations.   
 
Blood will be placed into tubes containing lithium heparin and potassium oxalate 
and sodium fluoride for the determination of plasma insulin and blood glucose 
concentrations, respectively.  Blood glucose concentrations will be determined 
immediately using the Glucose Oxidase method (Glucose Analyser 2; Beckman 
Instruments, Fullerton, CA).  The remaining blood sample will be kept on ice until 
centrifuged at 3200 g at 4  C for 10 min, upon completion of the clamp.  The 
plasma will be stored at –20  C for later analysis as previously described.   
 
The incremental trapezoidal area during the first 10 min of the test will be defined 
as first phase insulin secretion and the 10-60 min period will be defined as late 
phase insulin secretion 60.  Insulin sensitivity will be calculated from the rate of 











expressed per kilogram of lean body mass (determined previously by DEXA).  The 
function of the HPA axis in relation to insulin sensitivity will be examined.  
 
 
Measures of the HPA axis: 
 
The following tests will be performed in random order, separated by at least 2 days: 
 
a. IV CRH test:  
 
A cannula will be inserted into an antecubital vein at 12h30, at least 3 hr after 
the last meal.  At 13h00, 1 g CRH/kg body weight will be infused into the 
antecubital vein.  Blood samples (8 ml) will be drawn every 15 min for 2 hrs for 
the determination of serum ACTH and cortisol concentrations 39.   
 
Blood samples for cortisol determination will be placed into tubes containing 
lithium heparin and stored on ice until centrifuged at 3200 g for 10 min at 4  C.  
Plasma samples will be stored at –80  C until assayed with a commercial 
radioimmunoassay (RIA) (Orion Diagnostica, Espoo, Finland).  
 
Blood samples for ACTH determination will be placed into pre-chilled EDTA 
tubes containing aprotinin (500 U/ml) and centrifuged immediately at 3200 g for 
10 min at 4  C.  Plasma samples will be stored at –80  C until assayed with a 
commercial RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA).  
 
 
b. Low dose ACTH test:  
 
After an overnight fast (10-12 hr), an indwelling cannula will be inserted into an 
antecubital vein. Fifteen minutes later (between 08h30 to 09h00), 2 basal blood 
samples will drawn at 15 min intervals for the subsequent determination of 
plasma cortisol concentrations. Thereafter a 1 g bolus intravenous injection of 
synthetic ACTH (Cortrosyn) will be administered 62.  Further blood samples for 
cortisol determination will be drawn 15, 20, 30, 60 and 120 minutes after the 
injection.  Blood samples will be stored and assayed as described above.  
 
 
c. Low dose dexamethasone suppression test:  
 
3.5 g/kg body weight dexamethasone will be administered orally at 23h00.  
Subjects will report to the laboratory at 07h45, after an overnight fast (10-12 hr).  
A blood sample will be drawn from the antecubital vein at 08h00, after the 
subjects have rested quietly for 15 min 39.  The blood sample will be placed in 
tubes containing lithium heparin and EDTA for the subsequent determinations 
of plasma cortisol and dexamethasone concentrations, respectively.  Blood 
samples will be centrifuged immediately at 3200 g for 10 min at 4  C and stored 
at –80  C.  Plasma cortisol samples will be analysed as described above.  
Plasma dexamethasone samples will be assayed using a RIA using a specific 
















d. Urinary cortisol metabolites:   
 
A timed 24 hr urine sample will be collected for the measurement of urinary 
cortisol metabolites.  Urine aliquots will be stored at –200C for subsequent 
determination of cortisol and its metabolites (listed below) by gas 
chromatography and electron impact mass spectrometry following Sep-Pak C18 
extraction, as previously described 64,65.   
i. Free cortisol concentrations 
ii. Free cortisone concentrations 
iii. 5α-tetrahydrocortisol (5α-THF) concentrations 
iv. 5β-THF concentrations 
v. Tetrahydrocortisone (THE) concentrations 
vi. Creatinine concentrations (to assess the adequacy of the 24 
hr urine specimen)  
 




c. Blood pressure  
 
Blood pressure will be measured 3 times at 1-min intervals in each subject 
using an appropriately sized cuff and an Omron automated blood pressure 
monitor.  These measurements were taken after at least 20 min of seated rest.  
An average of the last 2 readings will be used in the analyses.  
 
During the trial, the subjects will be required to visit the laboratory on 6 occasions, 
including one day for the preliminary testing.   
 




A sub-sample of subjects from Phase 1 of the study will be recruited to undergo 
percutaneous adipose tissue biopsies while undergoing computerised tomography for 
Phase 1 of the study.   
 
 Black White 
Normal weight – BMI < 25 kg/m2 10 10 
Obese - BMI > 30 kg/m2 10 10 
Total subjects 20 20 
Refer to Addendum for sample size determinations.  
 
As it is not possible to obtain visceral adipose tissue using the percutaneous needle 
biopsy technique, a separate sample of 10 obese black and 10 obese white women 
who are undergoing abdominal surgery to correct benign conditions that do not alter 
endocrine function, such as peptic ulcers, gallstones, hernia repair, urinary tract 
disorders and certain gynaecological procedures, will be recruited for Phase 2 of the 

















Adipose tissue biopsies: 
 
After local anaesthesia with Lignocaine hydrochloride (2 % Xylotox S.E. Plain, Adcock 
Ingram, Bryanston, South Africa), adipose tissue samples of deep and superficial 
subcutaneous adipose tissue from the abdominal (right of the umbilicus) and gluteal 
areas (upper right quadrant) will be obtained using the percutaneous needle biopsy 
technique 66.  The deep and superficial adipose tissue will be separated at the level of 
the fascia superficialis, as described previously 19.  The biopsies will be performed 
under the direction of computerised tomography by a radiologist.  Approximately 1.5 
cm3 fat will be excised from each site through a 0.5-1 cm incision.  Adipose tissue will 
be frozen immediately in liquid nitrogen and stored at –80  C for subsequent analyses. 
 
In the sample of women undergoing benign abdominal surgery, adipose tissue samples 
(~ 2 g) from visceral and deep subcutaneous adipose tissue compartments will be 
obtained during the surgical procedure.  Samples will be snap-frozen in liquid nitrogen 
and be stored at –80  C for subsequent in vitro analyses as described below.   
 
 
Adipose tissue analyses: 
 
The adipose tissue samples from the different compartments will be used for the 
following in vitro analyses: 
 
a. Adipose 11 -HSD1 activity: 
 
Homogenised fat samples will be incubated with 1,2,6,7-3H4-cortisol to measure the 
11ß -HSD1 activity in the dehydrogenase direction (i.e. cortisol to cortisone) as 
described by Bujalska et al. 33 and Rask et al. 24.  Aliquots of the reaction will be 
separated on an HPLC with on-line liquid scintillation detection to measure the rate 
of cortisone production over a 30-hr period.   
 
 
b. Adipose gene expression and protein content: 
 
Total mRNA will be extracted from the adipose tissue according to standard 
methods. The expression of 11 -HSD1 33, angiotensinogen 67, TNF  68, PPAR  69, 
adiponectin 70, resistin 71, leptin 72 and the glucocorticoid receptor (GR) isoforms, 
GRα and GRβ 73 mRNA 74 will be determined using RT-PCR and/or Northern blot 
analysis.  The results will be normalised to the signal generated from -actin 
mRNA.  Where applicable, the levels of these proteins will be determined by 
Western blot analysis in a total protein extract from a separate portion of the 
adipose tissue sample.  
 
 
c. In vitro adipose lipolytic activity: 
 
Adipose tissue will be treated with collagenase, and the released adipocytes will be 
isolated and purified, as previously described 9.  The lipolytic activity of the purified 
adipocytes in response to cortisol, isoproterenol and insulin will be measured as 
described by Buthelezi et al. 9. 
 
 














No subjects will be enrolled into the study until the Research Ethics Committee of the 
University of Cape Town has approved the protocol and Patient Information Sheet, in 
writing.  The investigators maintain responsibility for informing the Research Ethics 
Committee in writing of any amendment to the protocol, or of any adverse events 
resulting from participation in the study.  The study will be performed in accordance 
with the principles of the Declaration of Helsinki, ICH Good Clinical Practice (GCP) and 
the laws of South Africa.  No subject will enter the study without signing informed 
consent, after and the investigator has provided a full and adequate oral and written 
explanation of the study, including possible risks.  Subjects have the right to withdraw 
from the trial at any stage without stating a reason, and trial personnel may also 
withdraw a subject from the study at any time.  Patients who violate the trial protocol 
should be withdrawn. Data generated from the trial will be stored in a computer 
database in a secure facility, and in a manner that maintains patients confidentiality.  
For data verification and quality control purposes regulatory authorities and/or 
members of the Research Ethics Committee may be allowed access to patient data 
under conditions of strict confidentiality. This is stated in the Patient Information Sheet. 














ADDENDUM A: SAMPLE SIZE DETERMINATION 
 
Sample size determination using a power of 80% (1-β) and an α-level of 0.01.  A Bonferroni 
correction factor was used to account for the 3 factors being investigated, namely, ethnicity, 
level of obesity and body fat distribution (α-level = 0.05/3 = 0.017)  
 
Parameter Smallest mean 
difference 
SD of score N per 
group 
Reference 
Comparisons reflect differences between black and white overweight women. 
Visceral fat area (cm
2
) 30 14 6 van der Merwe et al. 
14
 
Fasting [insulin] (pM/ml) 65 32 6 van der Merwe et al. 
8,15
 












0.12 0.047 4 
van der Merwe et al. 
14
 
Fasting [FFA] (pM) 450 70 4 van der Merwe et al. 
14
 




[ACTH] (AUC, pM) 
1278 183 12 




stimulated lipolysis by insulin 
(%) 
28 22 15 
Buthelezi et al. 
9
 





6.7 2.2 3 Rask et al. 
24
 
Urinary (5aTHF +5bTHF)/THE 
(mg/d) 






Plasma [cortisol] after DEX 
(nM) 
170 110 10 Rask et al. 
24
 
Serum [cortisol] after oral 
cortisone (AUC, nM.min) 
57 276 20 000 3 Rask et al. 
39
 
11 HSD1 activity (% 
conversion at 3 hr) 
34 17 6 Rask et al. 
24
 





4 2.7 11 
Rask et al. 
24
 
Urinary (5aTHF +5bTHF)/THE 
(mg/d) 
0.42 0.48 27 
Rask et al. 
24
 
Plasma [cortisol] after DEX 
(nM) 
85 110 34 
Rask et al. 
24
 
Serum [cortisol] after oral 
cortisone (AUC, nM.min) 
25 443 22 000 18 
Rask et al. 
39
 
11 HSD1 activity (% 
conversion at 3 hr) 
12 17 30 
Rask et al. 
24
 
Comparisons reflect differences between abdominally obese and peripherally obese women 
Plasma [cortisol] after CRH 
(AUC, nM.min) 
5788 3151 7 
Pasquali et al. 
29
 
Plasma [ACTH] after CRH 
(AUC, nM.min) 
192 105 7 
Pasquali et al. 
29
 
Urinary free [cortisol] (nM/m
2
) 15 4 2 Vicennati et al. 
30
 




SD, standard deviation; M, mean glucose disposal rate; M/I, mean glucose disposal 
rate, expressed as glucose sensitivity index; FFA, free fatty acids; AUC, area under the 
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a) Objectives of Literature review 
 
1. To gain information regarding the demographics of obesity globally as 
well as in South Africa 
2. To understand the impact obesity is having on health 
3. To gain information on fat physiology (fat is now considered to be an 
endocrine organ) as well as information on the adipokines and 
inflammatory mediators that are produced in fat and their functions in 
healthy individuals 
4. To learn about the mechanisms underlying the associations between 
obesity and certain diseases, especially insulin resistance and diabetes, 
hypertension, dyslipidaemia and atherosclerosis 
5. To examine the available literature regarding the relative contribution of 
abdominal and gluteal fat depots to metabolic risk factors including insulin 
resistance, hypertension, dyslipidaemia 
6. To examine published data investigating the metabolic effects of 
liposuction and identifying factors that may account for any disparate 
findings with respect to the effects of liposuction on the metabolic 
complications of obesity 
 
 
b) Literature search strategy 
 
 Pubmed search engine was used to locate journal articles. Examples of 
search words and phrases used include: obesity, adipokines, 
adipocytokines, names of specific adipokines and inflammatory mediators, 
diabetes and obesity, liposuction and obesity, metabolic effects of 
liposuction, liposuction and insulin resistance, ethnic differences in fat 
distribution 
 Advanced search function and Author searches were used 
 Related citations suggested by the search engine were also occasionally 
used 
 Some journal articles were obtained from the references of the journal 
articles already obtained 
 Some journal articles were obtained from my supervisor 
 Some journal articles (those not available on the UCT journal portal) were 
obtained directly from the author 





Adipokine: is a loosely applied term referring to any substance/ peptide hormone 
released by adipose tissue. 
 
Adipocytokine: is a loosely applied term referring to any substance/ peptide 
hormone released by adipose tissue but showing specific inclusion of 
inflammatory cytokines. 
 
Adiposopathy: is a term coined by Bays (18) and refers to the development of 











sedentary lifestyle in genetically prone individuals. Pathophysiologically it results 
in diverse metabolic and immune consequences leading to clinically evident 
metabolic disease.  
 
Large volume liposuction is defined as the removal of more than 5000mL of 
lipoaspirate (as defined by Liposuction task force of the American society of 
plastic surgeons)(87). 
 
Metabolic complications of obesity (MCO): Hypertrophic adipose tissue secretes a 
range of substances including abnormal amounts of various adipokines, pro-
inflammatory mediators and free fatty acids. This ultimately results in increased 
insulin resistance (impaired glucose tolerance and diabetes mellitus), 
dyslipidaemia, essential hypertension and accelerated atherosclerosis. 
 
Obesity is defined by a body mass index (BMI) greater than 30kg/m2 or more 
reliably (with regard to cardiovascular risk) by waist circumference of >102cm/ 





BMI- body mass index (kg/m2) 
CV risk- cardiovascular risk 
CRP – C-reactive protein 
DM – Diabetes mellitus 
FFA- free fatty acid 
IL-6 - interleukin 6 
IL-10 - interleukin 10 
IS- insulin sensitivity 
IR- insulin resistance 
LVL- large volume liposuction  
MCO- metabolic complications of obesity 
PAI – Plasminogen activator inhibitor 
PPAR-g - peroxisome proliferator-activated receptor gamma 
SAT- subcutaneous abdominal adipose tissue 
SSAT- superficial subcutaneous abdominal adipose tissue 
DSAT- deep subcutaneous abdominal adipose tissue 
TNF-∝ - tumour necrosis factor alpha 





























Obesity is an epidemic of the 21st century. In 2005 over a billion adults worldwide 
were overweight (Body mass index (BMI) >25kg/m2), with more than 300 million 
being obese (BMI >30kg/m2) (1). Obesity is aetiologically associated with a host of 
medical conditions and even certain cancers (see table 1 in addendum) (2, 3).  
In South Africa 87% of type 2 Diabetes, 68% of hypertensive disease, 45% of 
ischaemic strokes and 38% of ischaemic heart disease is attributable to obesity 
(4). Obesity was responsible for 7% of all South African deaths in 2000 (4) and 
has been declared the 5th leading independent cause of death in South African 
adults (5). It is as a result of these alarming statistics that obesity has been 
classified as a disease in its own right by the World Health organization (4).  
 
 
2. Fat Physiology and the Metabolic Complications of Obesity 
 
Although the association between obesity and these conditions is well established, 
the mechanisms via which obesity results in disease are less well understood. Of 
paramount importance is the fundamental shift in our understanding that adipose 
tissue is not a simple energy storage devise but an endocrine organ. Over 50 
adipokines are produced in adipose tissue (6). These adipokines are hormone-like 
communication molecules that play an integral role in normal physiology (7). In 
the obese state however, the abnormally hypertrophied adipocytes recruit 
macrophages and promote inflammation, as well as secreting of a range of 
substances including excessive amounts of free fatty acids (FFA) and abnormal 
amounts of adipokines (figure 1). This ultimately results in increased insulin 
resistance (IR), dyslipidaemia and essential hypertension (6). The term 
adiposopathy was coined by Bays to denote this pathological process (8).  




Figure 1) The metabolic complications of obesity 
FFA, free fatty acids; TNF-∝, tumour necrosis factor alpha; PAI-1, plasminogen 
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Leptin was the first adipokine to be discovered (in 1994). In the non-obese, leptin 
plays an important role in lipid metabolism as well as improving insulin 
sensitivity (9). In low energy states, leptin acts via the hypothalamus to stimulate 
an increased appetite as well as via the thyroid axis to slow the basal metabolic 
rate (10). 
Leptin concentrations increase in proportion to increasing obesity (adiposity).  
Excessively elevated leptin levels however, result in self induced leptin resistance 
(6), decreased insulin sensitivity (IS) and hypertension (via an induced 
hypercatecholaminaemia) (11). 
 
Adiponectin, another well-known adipokine, is produced by all adipocytes. Its 
secretion however, decreases with increasing adiposity (12). It plays important 
roles in increasing IS (13), improving free fatty acid metabolism, promoting a 
healthy endothelial cell function and decreasing atherosclerosis (partly by 
inhibition of tumour necrosis factor alpha (TNF-∝)) (14). Adiponectin levels are 
favorably increased by exercise, loss of weight (15) and certain anti-diabetic 
medications (Thiazolidinediones) (10). Adiponectin production is inhibited by 
pro-inflammatory mediators like interleukin-6 (IL-6) and TNF-∝ (16). The low 
adiponectin levels in obesity are associated with insulin resistance and 
hyperinsulinaemia (ultimately type 2 diabetes mellitus), dyslipidaemia and 
increased atherosclerosis (6, 10, 14-15).  
 
Peroxisome proliferator-activated receptor gamma (PPAR-g) is a ligand-activated 
nuclear transcription factor involved in the regulation of lipid and glucose 
metabolism, including adipocyte function and differentiation (17). No factor has 
been discovered that promotes adipogenesis in the absence of PPAR-g. Most pro-
adipogenic factors seem to function, at least in part, by activating PPAR-g 
expression or activity (9). Thiazolidinediones, a group of antidiabetic agents, are 
activators of both adiponectin as well as PPAR-g (18). In addition, the PPAR 
ligands suppress the production of proinflammatory cytokines mainly through 
suppression of nuclear transcription factor kappa-beta (19).  
 
Numerous other adipokines have been described but a detailed explanation of 
each adipokine is beyond the scope of this text. The role of several inflammatory 
mediators and FFA will however be briefly discussed below. 
 
 
2.2 Inflammatory mediators in obesity 
 
TNF-∝ plays important roles in obesity-related insulin resistance (19), increased 
FFA release into the circulation, hypertension and a reduction in adiponectin 
synthesis (20). TNF-∝ activates nuclear transcription factor kappa-beta, which 
orchestrates a series of inflammatory changes (especially in vascular tissue) that 
promotes atherosclerosis. (16).  
There is also a strong association between obesity and platelet-activation, with 
more than a three-fold increase in the excretion of platelet-derived thromboxanes 











activator inhibitor-1 in obesity, further promotes atherosclerosis and 
intravascular thromboses (22, 23). 
 
IL-6 is a circulating cytokine that is secreted by many cell types. Approximately 
one third of the circulating IL-6 is secreted from adipose tissue (24). Elevated 
plasma IL-6 levels positively correlate with human obesity and insulin resistance 
and predict the development of type 2 diabetes (25) and future myocardial 
infarction (26).  
 
Although C-reactive protein (CRP) is not an adipokine, its circulating 
concentrations are under the control of adipokines (especially IL-6) (16). Cross 
sectional analyses have shown strong and independent associations of CRP levels 
with measures of body fat (27). High levels of CRP in obesity also predict later 
development of diabetes (25, 28) and have become an important marker of 
vascular inflammation and a predictor of atherosclerosis (29). 
 
Interleukin-10 (IL-10) is a cytokine produced by macrophages and lymphocytes. It 
possesses multifaceted anti-inflammatory (16) and insulin sensitizing properties, 
partly through its inhibition of IL-6 and TNF-∝ (30). A low production capacity of 
IL-10 has been found to be associated with the metabolic syndrome and type 2 
diabetes (31).   
 
Interleukin 18 (IL18) is a pleotrophic pro-inflammatory cytokine that is secreted 
in adipose tissue and is a strong risk factor for the development of cardiovascular 
disease (32). Not only is IL-18 pro-atherogenic, but elevated IL-18 levels are also 
thought to cause myocardial dysfunction (33). Further, elevated IL-18 levels are 




2.3 Free Fatty Acids  
 
In addition to deranged expression of adipokines and inflammatory markers, 
perlipins (which play a role in preventing triacylglycerol breakdown in 
adipocytes) are deficient in obese adipocytes (6). This results in excessive 
amounts of FFA being released into the circulation. These circulating FFA are 
taken up by a variety of cells. Intracellular accumulation of FFA and their 
metabolites (especially in liver and muscle) hinder insulin’s ability to promote 
glucose uptake resulting in increased IR (35). In addition, the free fatty acids affect 
endothelial function (resulting in hypercoagulability) as well as promoting 
atherosclerosis (18). Raised FFA levels are also associated with the development 
of essential hypertension (36).  
 
 
 3. Adipose Tissue Depots  
 
Not all adipose tissue is associated with this metabolic deterioration in the 
presence of obesity.  
 
Peripheral obesity (e.g. gluteofemoral) has not been shown to be causally related 
to the metabolic complications of obesity (MCO) (11). Gluteofemoral fat exerts 
specific functional properties that are associated with an improved metabolic and 











are thought to be as a result of a beneficial adipokine profile as well as improved 
FFA metabolism (37).  
 
Central obesity on the other hand, is causally related to the MCO (38, 39). In this 
regard central obesity, measured by an increased waist circumference (male 
>102cm/ 40 inches, females >88cm/ 35 inches)(40), has consistently been 
associated with an increased risk of diabetes and cardiovascular disease 
independently of total adiposity, as measured by BMI (41-43).  
The central fat depot is however made up of several histologically and functionally 
distinct adipose tissue compartments including intra-abdominal and 
subcutaneous compartments.   
 
 
3.1 Abdominal Adipose Tissue Depots and Metabolic risk 
 
The abdominal adipose tissue compartment has contributions from both the intra-
abdominal and subcutaneous adipose tissue compartments.   
 
 
3.1.1 Visceral Adipose Tissue 
 
The intra-abdominal adipose compartment or visceral adipose tissue (VAT) is 
made up of both intra-peritoneal fat (mesenteric and omental fat depots) and 
retroperitoneal fat. Numerous studies have confirmed the direct association 
between VAT volume, inflammatory marker expression (44), cardiovascular risk 
(CV risk) and increasing IR (45-47).  
 
 
3.1.2 Subcutaneous Abdominal Adipose Tissue 
 
It was initially thought that the increased volume of VAT, which is closely related 
to the liver and pancreas, was wholly responsible for MCO. Matarasso et al, in 
1998, suggested that by performing large volume liposuction (LVL) the relative 
proportion of VAT to total body fat increased (as a result of decreasing the volume 
of subcutaneous abdominal adipose tissue (SAT)). They suggested that as the VAT 
volume is a risk factor for the metabolic complications of obesity (MCO), the 
metabolic effects of LVL may be deleterious and needed to be evaluated (48). 
In addition, it has been hypothesized (‘lipotoxicity theory’) (20) that excess VAT is 
more harmful than excess subcutaneous fat because lipolysis of VAT triglycerides, 
releases FFA into the portal vein, which are then taken to the liver (22, 40). 
Nielsen et al, have however found that only approximately 5% and 20% of portal 
vein FFA originated from VAT in lean and obese subjects respectively i.e. SAT 
supplies more FFA to the portal circulation, and hence the liver, than VAT (36, 49).  
In keeping with this, Abate found that SAT was more closely correlated to IR than 
VAT in his studies (50, 51). 
 
To complicate matters further, Scarpa’s fascia separates SAT into the superficial 
subcutaneous adipose tissue (SSAT) and the deep subcutaneous adipose tissue 
(DSAT). The fat in these two subcutaneous compartments are histologically 
distinct; the DSAT contains more loosely distributed fascial septae with larger 
more irregularly distributed fat lobules versus the SSAT with its compact fascial 
septae and small tightly packed fat lobules. The volume of adipose tissue is almost 
equally distributed between the DSAT and SSAT (52), but 76% of the DSAT is 











of the abdomen, which is the area where most abdominal liposuction is 
performed, consists largely of SSAT.  
It is therefore important to clarify the risk profile of each of these subcutaneous 
fat depots independently e.g. DSAT may be associated with the MCO but SSAT may 
be protective (and should therefore be preserved). 
 
Numerous studies have shown that an increased volume of DSAT is equally, if not 
more closely correlated with the development of essential hypertension, 
dyslipidaemia, impaired fibrinolysis, raised IR and increased CV risk than VAT 
volume (50, 54-57). 
 
The relationship between SSAT volume and this metabolic risk are however less 
clear. Several authors believe that SSAT accumulation is not associated with the 
MCO, and may even be protective (39, 58). Other authors, using similar study 
techniques but larger population samples, have found that SSAT behaves similarly 
to DSAT and VAT with respect to metabolic risk (50, 51, 54, 57).   
 
So it would seem that by reducing the volume of either VAT or DSAT the metabolic 
profile should improve. As the association of SSAT with the MCO is less clearly 
established, lipectomy of the SSAT (which occurs invariably during liposuction) 
could either improve or worsen the metabolic profile. Further research is 
therefore needed to clarify SSAT role in adiposopathy. 
 
In summary; adipose tissue is the largest endocrine organ in the body and in the 
obese state, the central portion seems to ‘malfunction’ resulting in the secretion of 
abnormal amounts and types of adipokines and inflammatory mediators that 
ultimately result in increased insulin resistance, essential hypertension and 
dyslipidaemia (2, 6, 20).  The triad of increased IR, dyslipidaemia and essential 
hypertension in the presence of abdominal obesity is known as the metabolic 
syndrome that promotes atherosclerosis, cardiovascular disease and ultimately 
premature death (18, 59). 
 
 
4. Ethnic Variations 
 
Libovitz and Banerji point out that there “seems to be large ethnic variations of 
metabolic activity of regional fat masses e.g. Asian Indians with the same fat mass 
and distribution as Caucasians have increased IR, FFA, CRP, plasminogen activator 
inhibitor-1 (PAI), and decreased adiponectin” (22).  
In the South African context, obese black women are phenotypically different to 
obese white women. Caucasian women accumulate more fat centrally compared 
to their African/ black counterparts, who accumulate more gluteofemoral and 
subcutaneous adipose tissue (SAT) (60) and develop prominent steatopygia. 
Further, black women have significantly less VAT than white women (~72 vs. 140 
cm2) (61, 62). Despite this, obese black Southern African women have double the 
prevalence of diabetes (7.0% vs. 3.6%) (63, 64) and hypertension (30% vs. 15%) 
(65) compared to obese white women who more commonly present with 
coronary heart disease and hypercholesterolaemia (66, 67).   
These findings would be supportive of our phenotypical observations. As white 
women tend to collect more central adiposity (largely due to more VAT), we 
would expect them to have a higher cardiovascular risk profile than the black 
women (as the waist circumference is the best anthropometric determinant of CV 
risk), however we would also expect them to have a stronger association with IR 











But obese black women, who collect more SAT and less VAT than obese white 
women, have a higher prevalence of type 2 diabetes mellitus and hypertension. 
This suggests that SAT may be more closely correlated with IR in obese black 
women than obese white women. Thus obese black women may potentially 
benefit more metabolically from a reduction in SAT volume (by for example 
liposuction) than obese white women. 
 
One of our aims therefore was to confirm the ethnic variation in fat distributions 
in South African women. In addition we aimed to determine the correlation 
between each of these fat depots (specifically SSAT vs. DSAT) and IR as well as 
their association with markers of cardiovascular risk. From these results we 




5. Lipectomy and the Metabolic Complications of Obesity 
 
Current public health initiatives have failed to reverse the obesity epidemic (68-
70). It would therefore be desirable to intervene and remove the ‘sick truncal fat’ 
(18) to curb the pathophysiological deterioration and potentially preventing the 
development of type 2 diabetes and the cardiovascular complications of obesity.  
 
In accordance with this Hansen et al found that reducing VAT volume (by 
omentectomy) doubled the IS in a dog model (35). Similarly Barzilai et al showed 
that the onset of diabetes, in Zucker Diabetic Fatty rats, could be delayed by 
removing visceral fat (71). Arner et al observed a significant long term 
improvement in IS in patients who had removal of less than 1kg of visceral fat 
(omentectomy) during bariatric surgery (gastric band), compared to those who 
did not have any visceral fat removed during bariatric surgery (72, 73). These 
studies suggest that omentectomy may be a useful modality to improve IS and 
possibly prevent the onset of diabetes in the obese. Unfortunately VAT is not 
easily accessible for surgical removal. SAT can however be easily removed via 
liposuction with minimal morbidity and risk (74-77). 
 
 
5.1 Liposuction and the Metabolic Complications of Obesity 
 
Ever since the realization that adipose tissue is metabolically active, there has 
been much debate on the effectiveness of liposuction as a means of improving 
insulin sensitivity and the metabolic profile (22, 78). Several prospective trials (7, 
23, 78-85) have been performed examining the effects of large volume liposuction 
(lipoaspirate volume of greater than 5000mL (86)) on insulin resistance, 
dyslipidaemia, inflammatory mediators and hypertension. The results of these 
trials were however conflicting and it is by no means clear what the metabolic 
consequences of large volume liposuction (LVL) are (see table 2 in addendum).  
 
 
5.1.1 Summary of the studies of the Metabolic Effects of Liposuction  
 
All of the above trials (table 2) examining the metabolic effects of liposuction were 
performed on obese or overweight premenopausal women. None of the studies 
commented on ethnicity of their patients. Liposuction was performed 
predominantly on the lower abdomen, but most patients also had some 











of SAT was predominantly removed from the lower abdomen (although the DSAT 
is generally the target area) or the volume of abdominal compared to peripheral 
fat removed.   
  
75% of the studies showed a statistically significant improvement in IS, but these 
positive studies represent 88.6% (233/263 patients) of the total number of 
patients studied. 71% of the studies showed a statistically significant 
improvement in the adipokine levels. Only 50% and 57% respectively, showed 
improved inflammatory markers and dyslipidaemia post liposuction. Of the 4 
studies that monitored blood pressure, only 2 found a significant improvement 
post liposuction.  
 
All of the studies that showed a significant improvement in IS, were performed in 
healthy (non-diabetic) women. The techniques used to measure the IS varied, but 
the largest trial published (123 patients by D’Andrea et al) (78) used the 
euglycaemic hyperinsulinaemic clamp technique (considered to be the gold 
standard) and found a statistically significant improvement in IS (R = 0.53, p < 
0.01). All of the trials that found an improvement in IS and also measured the 
adipokines and inflammatory mediators, found an improvement in these profiles 
too.  
 
The study by Bassetto et al (79) is an exception to the above. They performed 
megalipoplasty (lipoaspirate of >10L) in 15 obese women (the health status was 
not documented) and found a statistically significant improvement in IS at 6 
months of follow-up. There was however no significant improvement in the 
inflammatory marker or adipokine profile of their patients during the same 
period.  
 
The follow-up periods, of the positive outcome trials, varied from 21 days to 6 
months although the majority (83%) conducted patient follow-up for at least 3 
months. Interestingly, D’Andrea et al (78) found that no further significant 
improvement in the metabolic profile occurred beyond 21 days of follow-up. 
 
Only two studies found no significant improvement in IS (80, 82).  
Klein et al performed megalipoplasty on 8 healthy and 7 diabetic obese women 
(80). Only leptin showed a significant improvement in their follow-up period of 10 
to 12 weeks. This study was criticized for the small patient numbers and short 
follow-up duration. As a result, Klein et al performed a long-term follow-up (range 
1.5-4 years) on the same group of patients (84). However, only 7 women agreed to 
participate in the follow-up study (3 diabetics and 4 healthy). Although the 
women’s post liposuction weight remained stable, 4 of the 7 women had changes 
in their medication (the 3 diabetics had changes in their anti-diabetic medication 
and one healthy patient was started on lipid modulating therapy). The long-term 
follow-up did not demonstrate any improvement in any of the metabolic 
parameters that were measured in the first trial.  
 
Robles-Cervantes et al performed liposuction in 15 healthy women with a BMI 
range from 25-27 kg/m2 (82). They measured IS as well as the lipid profile, but 
only found a significant improvement in the dyslipidaemia during their follow-up 
period of 3 weeks.  
 
Two studies were excluded from the liposuction table. The first, by 
Rizzo et al (87), examined the metabolic effects of lower abdominal 











obese women. Notably, they report a significant improvement in the IS (r = 0.53, p 
< 0.01), the adipokine levels (p <0.03), inflammatory marker profiles (p < 0.001), 
the dyslipidaemia (including FFA levels) and the blood pressure by lower 
abdominal dermolipectomy. 
In contrast, Samdal et al (85) studied the effect of LVL on sex hormones, and 
glucose and lipid metabolism in 9 women. Their patients varied from lean (BMI 
23.5kg/m2) to morbidly obese women (BMI 39kg/m2). Four of their patients only 
had fat removed from extra-abdominal regions, but these results were grouped 
together with those having abdominal liposuction.  An oral glucose tolerance test 
was performed and the serum insulin concentration measured. Extrapolations 
regarding the IS were drawn from these measurements without directly 
calculating the IS. In addition the patients diets, exercise regimes and weights 
were not regulated during the study period. As a result of these findings, this 




5.1.2 Possible Explanations for the Conflicting results of these studies 
 
There are several explanations that could account for the variable outcomes of 
these trials:  
1. Small number of patients in most of the trials  
2. Clinical condition (healthy vs. diabetic) of the patients  
3. Ethnicity of the patients  
4. Technique of IS measurement (euglycaemic hyperinsulinaemic clamp vs. 
HOMA) 
5. Type and site of fat removal (e.g. gluteofemoral vs. SAT, DSAT vs. SSAT) 
6. Variable lipectomy volume (lipoaspirate volumes varied from 3.5L (7) to 
26.3L (79)) 
7. Duration of follow-up 
8. Failure to regulate amount of exercise and dietary intake preoperatively 
and for the duration of the follow-up 
 
 
The conflicting results of these clinical trials on the metabolic effects of large 
volume liposuction stimulated our interest in the ethnic variations of fat 
distribution and the metabolic activity of regional fat depots.  
 
 
6. Aims and Objectives of the current study  
 
1. To determine the ethnic specific variations (black vs. white) in fat 
distribution of lean compared to obese South African women. 
2. To determine the ethnic specific associations of subcutaneous fat depots 
and insulin resistance (especially SSAT which is the least investigated fat 
depot with regard to metabolic risk). 
3. To determine the ethnic variations in the expression of adipokines and 
inflammatory markers in each of the fat depots and their associations with 
IS.  
4. To draw hypotheses from our results that may account for the conflicting 
results of previous studies examining the effects of liposuction on IR, 

























–Ischaemic heart disease 
 
Neurological: –Strokes/ CVAs 
–Neurodegenerative disorders e.g. 
dementia 
 
Airway: –Asthma  
–Sleep apnoea 
 
Other: –Some cancers (endometrial, 
colonic, renal and postmenopausal 
breast cancer) 
–Fatty liver 




Table 1) Obesity related diseases.  
Obesity is considered to be a central feature that increases the risk for a vast array 











Table 2) Studies of the metabolic effects of liposuction  

















































































g) References for literature review: 
 
1. Haslam DW, James WPT. Obesity. Lancet 2005; 366: 1197-1209 
2. Bays HE, Gonzalez-Campoy JM, Bray GA, et al. Pathogenic potential of adipose 
tissue and the metabolic consequences of adipocytes hypertrophy and increased 
visceral adiposity. Expert Rev. Cardiovasc Ther 6(3): 343-368; 2008 
3. Hamad GC: State of  art bariatric surgery for weight loss in the morbidly obese 
patient. Clin Plastic Surg 2004; 31: 591-600 
4. Joubert J, Norman R, Bradshaw D, et al. Estimating the burden of disease 
attributable to excess body weight in South Africa in 2000. S Afr Med J 2007; 
97(8): 683-690 
5. Norman R, Bradshaw D, Schnieder M, et al. A comparative risk assessment for 
South Africa in 2000: Toward promoting health and preventing disease. S Afr 
Med J 2007; 97(7): 636-641  
6. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation 
and metabolism. Am J Clin Nutr 2006; 83(Suppl): 461S-465S  
7. Giugliano G, Nicoletti G, Grella E, et al. Effects of liposuction on insulin resistance 
and vascular inflammatory markers in obese women. Br J Pl Surg 2004; 57: 190-
94  
8.    Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause 
metabolic disease? Future Lipidology. 2006; 1:389-420 -??use under 3.1 p5 
instead?? 
9. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. 
Molecular cell biol 2006; 7:885-890 
10. Havel PJ. Lipid modulators of islet cell function. Update on adipocyte hormones 
and regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 
2004; 53: S143-S151 
11. Bays HE, Fox KM, Grandy S. Anthropometric measurements and diabetes 
mellitus: Clues to the “Pathogenic” and “Protective” potential of adipose tissue. 
Meta synd and Related disorders 2010; 8(4): 307-15 ). 
12. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparisons of the release 
of adipokines by Adipose tissue matrix, and adipocytes from visceral and 
subcutaneous abdominal adipose tissues of obese humans. Endocrinlogy 2004; 
145(5): 2273-2282 
13. Vendrell J, Broch M, Villarosa N et al. Resistin, Adionectin, Ghrelin, Leptin and 
proinflammatory cytokines: Relationships in Obesity. Obes Res 2004; 12:962-71 
14. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines as emerging mediators 
of immune response and inflammation. Rheumatology 2007; 3(12): 716-24 
15. Stefan N, Stumvoll M. Adiponectin- Its role in metabolism and beyond. Horm 
meta res 2002; 34: 469-74 
16. K Esposito, giugliano G, Nicolo S, Dario G. Role of Adipokines in the Obesity-
inflammation relationship: The effect of fat removal. Plast recon surg 2006; 
118(4): 1048-57 
17. Schoonjans K,  Staels B, Auwerx J.  The peroxisome proliferator activated 
receptors (PPARs) and their effects on lipid metabolism and adipocyte 
differentiation. Biochemica et Biophysica acta 1996; 1302: 93-109 
18. Bays HE. “Sick fat”, Metabolic disease, and atherosclerosis. Am J Med. 2009, 
122;1A: S26-S37 
19. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7 
20. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity and the paradox 











21. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M et al. 
Platelet activation in obese women: role of inflammation and oxidant stress. 
JAMA 2002; 288: 2008-14 
22. Lebowitz HE, Banerji. Point: Visceral adiposity is causally related to Insulin 
resistance. Diabetes Care 2005; 28(9): 2322-325 
23. Giese SY, Bulan EJ, Commons GW, et al. Improvements in cardiovascular risk 
profile with larger volume liposuction: A pilot study. Plast Reconstr Surg 2001; 
108(2): 510-519  
24. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to 
adiposity, insulin action, and insulin secretion. Obes. Res 2001; 9: 414 
25. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk 
of developing type 2 diabetes mellitus. JAMA 2001; 286: 327 
26. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and 
the risk of future myocardial infarction among apparently healthy men. 
Circulation 2000; 101: 1767 
27. Festa A, D’Agostino R, Jr. Howard G, et al. Chronic subclinical inflammation as 
part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis 
Study (IRAS). Circulation 2000; 102: 42 
28. Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in 
relation to the development of diabetes and metabolic syndrome in the Mexico 
City Diabetes Study. Diabetes Care 2002; 25: 2016  
29. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers 
of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. 
Med. 2000; 342: 836 
30. Gunnett CA, Heistad DDN, Faraci FM. Interleukin-10 protects nitric oxide-
dependent relaxation during diabetes: Role of superoxide. Diabetes 2002; 51: 
1931 
31. van Exel E, Gussekloo J, de Craen AJ, et al. Low production capacity of 
interleukin-10 associates with the metabolic syndrome and type 2 diabetes: The 
Leiden 85-Plus Study. Diabetes 2002; 51: 1088 
32. Skurk T, Kolb H, Muller-Scholze S, Rohrig K, Hauner H, Herder C. The 
proatherogenic cytokine IL-18 is secreted by human adipocytes. Eur J of 
Endocrinol 2005; 152: 863-68 
33. Wold baek, PR, Sande JB, Stromme TA, Lunde PK, Djurovic S, Lyberg T, 
Tonnessen T. Daily administration of interleukin-18 causes myocardial 
dysfunction in healthy mice. Am J Physiol Heart Circ. Physiol 2005; 289, H708-
714 
34. Hung J, McQuillan BM, chapman CML, Thompson PL, Beilby JP. Elevated IL-18 
levels are associated with the metabolic syndrome independent of obesity and 
insulin resistance. Arterioscler Thromb Vasc Biol. 2005; 25: 1268-73 
35. Hansen E, Hajri T, Abumrad NN. Is all fat the same? The role of fat in the 
pathogenesis of the metabolic syndrome and type 2 diabetes mellitus. Surgery 
2006; 139(6): 711-16 
36. Lebowitz HE, Banerji. Point: Visceral adiposity is Not causally related to Insulin 
resistance. Diabetes Care 2005; 28(9): 2326-328 
37. Manolopoulos KN, Karpe F, Frayn KN. Gluteopfemoral body fat as a determinant 
of metabolic health. Int J obesity 2010: 1-11. 
38. Wexler DJ, Hu FB, Manson JE, et al. Mediating effects of inflammatory markers on 
insulin resistance associated with obesity. Obesity Research 2005; 13(10): 1772-
83 
39. Kelly DE, Thaete FL, Troost F, et al. Subdivisions of subcutaneous abdominal 
adipose tissue and insulin resistance. Endocrinal Metab 2000; 278: E941-948 












41. M, Gaskill SP, Haffner SM,Stern MP. Waist circumference as the best predictor of 
noninsulin dependant diabetes (NIDDM) compared to body mass index, 
waist/hip ratio and other anthropometric measurements in Mexican Americans: 
a 7-year prospective study. Obes Res. 1997; 5: 16-23 
42. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index 
explains obesity-related health risk. Am J Clin Nutr. 2004; 79:379-84 
43. Carey DG, Jenkins AB, Campbell LV, Freund J, chrisholm DJ. Abdominal fat and 
insulin resistance in normal and over-weight women: direct measurements 
reveal a strong relationship in subjects at both low and high risk of NIDDM. 
Diabetes. 1996; 45: 633-8 
44. Alvehus M,BurenJ, Sjostrom M, Goedecker J, Olsson T. The human visceral fat 
depot has a unique inflammatory profile. Obesity 2010; 18: 879-883 
45. Goodpaster BH, Kelly DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on 
the regional fat distribution and insulin sensitivity in obesity. Diabetes 1999; 48: 
839- 47 
46. Arner P. Not all fat is alike. Lancet 1998 2;351(9112):1301-2 
47. X25.  Despres,J.P. Health consequences of visceral obesity. Ann Med 2001; 33, 
534-541  
48. Matarasso A, Kim RW, Fral JG. The impact of liposuction on body fat. Plast recon 
surg 1998; 102(5): 1686-9 
49. Nielsen S, Guo ZK, Johnson CM, Hensrud DD and Jensen MD. Splanchnic lipolysis 
in human obesity. J clin Invest 2004; 113:1582-8 
50. Abate N, Garg A, Peshock RM, et al. Relationship of generalized and regional 
adiposity to insulin sensitivity in men: J Clin Invest. 1995; 96: 88-98  
51. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM. 
Relationship of generalized and regional adiposity to insulin sensitivity in men 
with NIDDM. Diabetes 1996; 45: 1684-93 
52. B- one that has 19 attached- Perez RA: Liposuction and Diabetes type 2 
development risk reduction in the obese patient. Medical Hypotheses 2007; 68: 
393-96 
53. Misra A, Garg A, Abate N, Peshock R, Stray-Gundersen J, and Grundy S. 
Relationship of anterior and posterior subcutaneous abdominal fat to insulin 
sensitivity in nondiabetic men. Obes Res 1997; 5: 93-99 
54. Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism with 
superfiscial subcutaneous rather than visceral adipose tissue is associated with 
features of the metabolic syndrome in South African women. Clin Endocrinology 
2006; 65: 81-87 
55. Walker GE, Verti B, Marzullo P, et al. Deep subcutaneous tissue: A distinct 
abdominal adipose depot. Obesity 2007;15(8): 1933-943  
56. Bassetto F, Gharb BB, Rampazzo A, Busetto L, Pigozzo S, Nolli M. Reply to: Effect 
of liposuction on insulin resistance and vascular inflammatory markers in obese 
women. British J Plast Surg. Doi:10.1016/j.bjps.2005.02.017 
57. Goodpaster BH, Thaete FL, Simoneau JA, Kelly DE. Subcutaneous abdominal fat 
and thigh muscle composition predict insulin sensitivity independently of 
visceral fat. Diabetes 1997; 46: 1579- 1585 
58. Misra A, Garg A, Abate N, Peshock R, Stray-Gundersen J, Grundy S. Relationship 
of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in 
nondiabetic men. Obes Res 1997; 5: 93–99 
59. Reaven GM. The role of insulin resistance and hyperinsulinaemia as risk factors 
for diabetes and cardiovascular disease. Arteriosclersois 1986; 6: 123)  
60. Lovejoy JC, de la Bretonne JA, Klemperer M,Tulley R. Abdominal fat distribution 
and metabolic risk factors: effects of race. Metabolism 1996; 45: 1119-124 
61. Punyadeera C. et al. Ethnic differences in lipid metabolism in two groups of 











62. Punyadeera C. et al. Weight-related differences in glucose metabolism and free 
fatty acid production in two South African population groups. Int J Obes Relat 
Metab Disord 2001; 25, 1196-1205  
63. Joffe BI, Seftel HC. Diabetes mellitus in the black communities of Southern Africa. 
J Int Med 1994; 235, 137-142  
64. Omar MA, Seedat MA, Motala AA, Dyer RB, Becker P. The prevalence of diabetes 
mellitus and impaired glucose tolerance in a group of urban South African 
blacks. S Afr Med J 1993; 83, 641-643  
65. Seedat,Y.K. Race, environment and blood pressure: The South African 
Experience. J Hypertens 1983; 1, 7-12  
66. Steyn,K., Fourie,J. & Bradshaw,D. The impact of chronic diseases of lifestyle and 
their major risk factors on mortality in South Africa. S Afr Med J 1992; 82, 227-
231  
67. Schutte AE, Huisman HW, Van Rooyen JM, Schutte R, Malan L, Reimann M, De 
Ridder JH, van der Merwe A, Schwarz PE, Malan NT. Should obesity be blamed 
for the high prevalence rates of hypertension in black South African women? J 
Hum Hypertens. 2008; 22(8): 528-36 
68. Puoane T, Steyn K, Bradshaw D, et al. Obesity in South Africa: The South African 
demographic and health survey. Obesity Research 2002; 10(10): 1038-1048 
69. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends 
in body-mass index since 1980: systematic analysis of health examination 
surveys and epidemiological studies with 960 country-years and 9·1 million 
participants. Lancet 2011; 377(9765): 557-567 
70. Isik F. Discussion of the Role of Adipokines in the Obesity-inflammation 
relationship: The effect of fat removal. Plast recon surg 2006; 118(4): 1058-59 
71. Barzalai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, et al. Surgical removal of 
visceral fat reverses hepatic insulin resistance. Diabetes 1999; 48:94-8 
72. Thome A, Lonnqvst F, Apelman J, Heller G, Arner P. A pilot study of the long term 
effects of a novel obesity treatment: omentectomy in connection with adjustable 
gastric banding. Int J Obesity Relat Meta Disord 2002; 26:193-9 
73. P Arner. Metabolic effects of liposuction: Yes or No? Letter to editor. N Engl J Med 
2004; 351(13): 1354-5 
74. Hunstad JP, Aitken ME. Liposuction: Techniques and guidelines. Clin Plastic surg 
2006; 33: 13-25 
75. Gasperoni C, gasperoni P. Subderaml liposuciton: Long-term experience.  Clin 
Plastic surg 2006; 33: 63-73 
76. Toledo L, Mauad R. complications of body sculpture: Prevention and treatment. 
Clin Plastic surg 2006; 33: 1-11 
77. Illouz YG. Complications of liposuction. Clin Plastic surg 2006; 33: 129-63 
78. D’Andrea F, Girella R, Rizzo MR, et al.: Changing the metabolic profile by large 
volume liposuction: A clinical study conducted with 123 obese women. Aesth Pl 
Surg 2005; 29: 472-478  
79. F Bassetto, Gharb BB, Rampazzo A, Busetto L, Pigozzo S, Nolli M. Reply to: Effect 
of liposuction on insulin resistance and vascular inflammatory markers in obese 
women. Br J Plast surg. Doi: 10. 101/j.bjps.2005.02.016 
80. Klein S, Fontana L, Young L, et al. Absence of an effect of liposuction on insulin 
action and risk factors for coronary heart disease. N Engl J Med 2004; 350(25): 
2549-557 
81. Gonzalez-Ortiz M, Robles-Cervante J, Cardenas-Camarena L, et al. The effects of 
surgically removing subcutaneous fat on the metabolic profile and insulin 
sensitivity in obese women after large volume liposuction treatment. Horm 











82. Robles-Cervantes JA, Yanez-Diaz S, Cardenas-Camarena L. Modification of 
insulin, glucose and cholesterol levels in nonobese women undergoing 
liposuction. Is liposuction metabolically safe? Ann Plast Surg 2004; 52(1): 64-7 
83. Esposito K, Giugliano G, Giugliano D. Metabolic effects of liposuction- yes or no? 
Letter to the editor. N Engl J Med 2004; 351(13): 1354-56 
84. Mohammed SB, Cohen S, Reeds D, Young LV, Klein S. Long term effects of large-
volume liposuction on metabolic risk factors for coronary heart disease. Obesity 
2008; 16(12): 2648-651 
85. Samdal F, Birkeland KI, Ose L, Amland PF. Effect of large-volume liposuction on 
sex hormones and glucose and lipid metabolism in females. Aesth Plast surg 
1995; 9: 131-35 
86. Trussler A. Body contouring. Seletive readings plastic surgery 2008; 10(22): 1-47 
87. Rizzo MR, Paolisso G, Grellat R, barbieri M, Grellat E, Ragno E, Nicoletti G, 
D’andrea F. Is dermolipectomy effective in improving insulin action and 





















Part C: Results of the study in the form of an article 
 
Ethnic-specific associations between 
abdominal and gluteal fat distribution 
and the Metabolic complications of 






MMED by Philip Hayes 
Student number: HYSPHI 003 
 
 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 
Dept of Plastic and Reconstructive Surgery 
 
 
Supervisor: Dr J Goedecke 




List of Contents of Literature Review 
 
a) Abstract 

























Ethnic-specific associations between abdominal and 
gluteal fat distribution and the metabolic 
complications of obesity: Implications for the use of 
Liposuction 
 
Philip Hayes1, Kevin Adams1 and Julia Goedecke2,3 
 
Background: Adipose tissue is no longer considered to simply be an energy storage depot but is now 
considered to be an endocrine organ. Enlarged adipocytes of obese individuals release a range of 
adipokines and inflammatory mediators that promote insulin resistance and ultimately the 
development of type 2 diabetes and cardiovascular disease. Ever since the realization that adipose 
tissue is metabolically active, there has been much debate on the effectiveness of liposuction as a 
means of improving insulin sensitivity and the metabolic profile.  
 
Aim: To examine the ethnic and physiological differences of abdominal and gluteal fat compartments 
and their relationship to insulin sensitivity. 
This study will provide information on the potential metabolic benefits of liposuction in women of 
different ethnic origin.  
 
Methods: Fifty-four lean and obese, black and white premenopausal women with no known disease 
were recruited for the study.  Body composition, fat distribution (DXA and CT), insulin sensitivity 
(frequently sampled intravenous glucose tolerance test with minimal model analysis) and serum 
levels of lipids, adipokines (leptin and adiponectin) and inflammatory mediators (IL-18) were 
measured. Biopsies were taken from the deep and superficial subcutaneous abdominal adipose 
tissue (SAT) and gluteal depots for the measurement of leptin, adiponectin and IL-18 mRNA levels. 
 
Results: When matched for body fatness, obese black women had less visceral adipose tissue (VAT) 
(98.4±11.3 vs. 147.2±11.8 p<0.05), but more superficial SAT (325.1±14.8 vs. 247.3 ± 15.4 p<0.01) 
and gluteal fat (4.09±0.18 vs. 3.54±0.2 p=0.043) than their white counterparts. There were no ethnic 
differences in deep SAT (P=0.92). Nonetheless, both the lean and the obese black women were less 
insulin sensitive (IS) than white women (IS lean: 2.8 0.5 vs. 6.1 0.5 and IS obese: 1.8 0.5 vs. 3.8 0.5 
x10-4min-1/mU/l, P<0.01). IS correlated with VAT in white, but not black women (R=-0.53, P<0.01 
and R=-0.31, P=0.21, respectively). In contrast, IS correlated with deep SAT (whites R=-0.54, p<0.01, 
blacks R=-0.59, p<0.01) and superficial SAT (whites R=-0.55, p<0.01, blacks R=-0.50, p=0.01) in both 
ethnic groups. In addition, gynoid (gluteal) fat mass was found to be inversely associated IS (R= -
0.46, p=0.033) in black but not white women (r= 0.28, p=0.22), after adjusting for body fatness. 
Within the adipose tissue depots, we found that the gluteal depot had higher inflammatory marker 
(IL-18 mRNA: p<0.001) and leptin mRNA levels (p<0.001), than the DSAT and SSAT abdominal 
depots, in both ethnic groups. Despite this, only gluteal adiponectin mRNA levels (r=0.44, p=0.03) in 
black women and SSAT leptin mRNA levels (r =-0.54, p=0.01) in white women were associated with 
IS.  
 
Conclusion: We found that both lean and obese black South African women were more insulin 
resistant than their white counterparts. SSAT and DSAT volumes correlated inversely with IS in both 
races, but obese black women had larger volumes of SSAT (and therefore SAT) than obese white 
women. VAT was only associated with decreasing IS in white women, whereas the gluteal depot was 
only associated with decreasing IS in black women. Based on these findings, we hypothesise that a 
reduction in the SAT volume may improve IS and the metabolic profile in both black and white 
women, but may be more beneficial in black compared to white women. 
Further, a reduction in gluteal fat volume by liposuction may be beneficial for black, but not white 
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Obesity is an epidemic of the 21st century (1) and is aetiologically associated with 
a host of medical conditions (including type 2 diabetes mellitus and 
cardiovascular disease) and even certain cancers (2, 3). Although the association 
between obesity and these diseases is well established, the mechanisms via which 
obesity results in disease are less well understood. Of paramount importance is 
the fundamental shift in our understanding that adipose tissue is not a simple 
energy storage devise but an endocrine organ (4).  
 
In obesity however, hypertrophic truncal adipose tissue has deranged function 
and secretes a variety of substances including abnormal amounts of adipokines, 
free fatty acids and chronic inflammatory mediators (5).  This results in increased 
insulin resistance (IR), dyslipidaemia and essential hypertension (2) and 
promotes the development of type 2 diabetes mellitus (6), atherosclerosis, 











Following the realization that adipose tissue is metabolically active, there has 
been much debate regarding the effectiveness of liposuction as a means of 
improving insulin sensitivity (IS) and the metabolic profile (8, 9). Several 
prospective clinical trials (8, 10-16) have been performed examining the effects of 
large volume liposuction (LVL) on IR, dyslipidaemia, inflammatory mediators and 
hypertension. The results of these trials are however conflicting (see table 1 in 
addendum).  
 
Approximately 75% of the quoted studies (8, 10, 13, 14, 16), which represent 
88.6% (233/263 patients) of the total number of patients studied, showed a 
statistically significant improvement in IS and the metabolic profile in both 
overweight (body mass index (BMI) >25kg/m2) and obese (BMI >30kg/m2) non-
diabetic women. In contrast, other studies (12, 15) showed no significant 
improvement in the metabolic profile and suggested that liposuction was purely 
cosmetic and that loss of weight, by dieting and exercise, was needed to improve 
the metabolic profile (17).  
 
There are several reasons that could account for these conflicting results. For 
example, the majority of the studies had very small patient population sizes (less 
than 15) with the clinical status of the patients varying from healthy to diabetic. In 
addition, the technique used to measure IS and the duration of follow-up varied 
significantly between trials. Additional factors that could influence the outcome of 
a trial examining the metabolic effects of LVL are the site and volume of fat 
removal as the metabolic activity and profile of regional fat depots varies. 
 
In this regard central obesity, measured by an increased waist circumference 
(male >102cm/ 40 inches, females >88cm/ 35 inches) (18), has consistently been 
associated with an increased risk of diabetes and cardiovascular disease 
independently of total adiposity, as measured by BMI (19-21). The central fat 
depot however, includes contributions from the retroperitoneal and intra-
abdominal fat (or visceral adipose tissue (VAT)) as well as the subcutaneous 
abdominal adipose tissue (SAT). However, only the volume of SAT, and not VAT, 
can be easily reduced surgically via liposuction.  
SAT is further divided into the superficial subcutaneous abdominal adipose tissue 
(SSAT) and the deep subcutaneous abdominal adipose tissue (DSAT) by Scarpa’s 
fascia. The fat in these two subcutaneous compartments are histologically distinct; 
the DSAT contains more loosely distributed fascial septae with larger, more 
irregularly distributed fat lobules, versus the SSAT with its compact fascial septae 
and small tightly-packed fat lobules (22). 
 
It was initially thought that the increased volume of VAT, which is closely related 
to the liver and pancreas, was responsible for the MCO (21, 23, 24). Numerous 
studies have however shown that DSAT is equally, if not more closely correlated 
with the development of essential hypertension, dyslipidaemia, impaired 
fibrinolysis, raised IR and increased cardiovascular risk (CV risk) than VAT 
volume (25-28).  
 
The relationship between SSAT and this metabolic risk is however less clear. 
Several authors believe that SSAT accumulation is not associated with the MCO, 
and may even be protective (29, 30). Other authors, using similar study 
techniques but larger population samples, have found that SSAT behaves similarly 
to DSAT and VAT with respect to metabolic risk (25, 26, 28, 31). However, as the 
association of SSAT with the MCO is not clearly established, lipectomy of SSAT 










metabolic profile. Further research is therefore needed to clarify SSAT role in 
obesity. 
 
One possible explanation for the conflicting results of these SSAT studies, as well 
as for the conflicting results of the studies examining the metabolic effects of LVL, 
is the influence that ethnicity has on the metabolic activity of the regional fat 
depots (32, 33). 
In this regard Libovitz and Banerji showed that Asian Indians with the same body 
fat and distribution as Caucasians have increased: IR, free fatty acids (FFA), C-
reactive protein (CRP), plasminogen activator inhibitor-1 (PAI); and decreased 
adiponectin (9). In the South African context, obese black women are 
phenotypically different to obese white women. Caucasian women accumulate 
more fat centrally compared to their African/ black counterparts, who accumulate 
more gluteofemoral and subcutaneous adipose tissue (SAT) (32) and develop 
prominent steatopygia. Further, black women have significantly less VAT than 
white women (~72 vs. 140 cm2) (34, 35). Despite this, obese black Southern 
African women have double the prevalence of diabetes (7.0% vs. 3.6%) (36, 37) 
and hypertension (30% vs. 15%) (38) compared to obese white women who more 
commonly present with coronary heart disease and hypercholesterolaemia (39, 
40). 
This suggests that SAT volume in black women may be more strongly correlated 
with the development of IR than in white women. Thus, obese black women may 
benefit more metabolically from a reduction in SAT volume (by for example 
liposuction) than obese white women. 
 
Therefore the aims of our study are: 
1. To determine the ethnic specific (black vs. white) variations in fat 
distribution of lean compared to obese South African women 
2. To determine the ethnic specific associations of these fat depots with 
insulin resistance (especially SSAT which is the least investigated fat depot 
with regard to metabolic risk) 
3. To determine the ethnic variations in the expression of adipokines and 








Fifty-four South African women were recruited by advertisement in local 
newspapers and from local church groups, community centers, and universities. 
The study population consisted of 14 normal weight (body mass index [BMI] 18-
25 kg/m2) black, 13 normal weight white, 14 obese (BMI >30 kg/m2) black, and 
13 obese white South African women.  
Inclusion criteria were as follows: 
(1) age from 18 to 45 years; (2) no known diseases or taking medication for 
dyslipidemia, diabetes, hypertension, HIV/ AIDS, or any other metabolic 
disorders; (3) not currently pregnant, lactating, or postmenopausal; and (4) of 
South African ancestry. The study was approved by the Human Research Ethics 
Committee of the Faculty of Health Sciences of the University of Cape Town. 
Before participating in the study, procedures and risks were explained to the 












2.2 Study design 
 
2.2.1 Body composition and blood pressure measurement 
 
Basic anthropometric measurements including weight, height, and waist (at the 
level of the umbilicus) and hip (largest gluteal area) circumference were taken. 
Body fat percentage and the gynoid region of interest (41) were measured using 
dual-energy x-ray absorptiometry (Discovery-W, Software version 4.40; Hologic, 
Bedford, MA) the measurement of which has a coefficient of variation of 1.7%. 
Abdominal visceral (VAT) and subcutaneous adipose tissue (SAT) area was 
measured at the level of L4-L5 lumbar vertebrae using computed tomography 
(Toshiba X-press Helical Scanner, Tokyo, Japan). The fascia superficialis was used 
to distinguish between the deep (DSAT) and superficial (SSAT) SAT depots. 
Blood pressure was measured in a seated position after 5-10 minutes of rest using 
an automated blood pressure monitor (Omron 711; Omron health Care, Hamburg, 
Germany). The average of three measurements taken at 1 minute intervals was 
used in the analysis.  
 
 
2.2.2 Measurement of glucose tolerance, insulin sensitivity and insulin release 
 
After an overnight fast, a blood sample was taken for the determination of fasting 
plasma glucose, serum insulin, lipids, adiponectin, leptin and high-sensitivity C-
reactive protein (CRP) levels and interleukin-18 (IL-18). Subjects then underwent 
an insulin-modified frequently sampled intravenous glucose tolerance test 
(FSIGT) to quantify insulin sensitivity. Baseline samples were drawn at −15, −5, 
and −1 minute before the infusion of glucose (50% dextrose; 11.4 g/m2 body 
surface area) over 60 seconds at time 0. At 20 minutes, human insulin (0.02 U/kg; 
Actrapid, Novo Nordisk, Sandton, South Africa) was infused over 5 minutes at a 
constant rate (i.e. a slow bolus of insulin). Plasma glucose and serum insulin 
concentrations were measured in the 3 baseline samples and the 32 samples 
drawn over 240 minutes after commencement of the glucose infusion. Glucose 
and insulin data from the FSIGT were used to calculate the insulin sensitivity 
index (IS) using the minimal model of glucose kinetics of Bergman et al (42). The 
samples were centrifuged at 3000 rpm for 10 minutes at 40C, the plasma was 
stored at -200C for subsequent analysis of glucose concentrations, and the serum 
was stored at -800C for the subsequent analysis of insulin concentrations. 
 
 
2.3 Biochemical analysis 
 
Plasma glucose concentrations were determined using the glucose oxidase 
method (YSI 2300 STAT PLUS; YSI Life Sciences, Yellow Springs, OH). Serum 
insulin concentrations were determined by immunochemiluminometric assays 
using the ADVIA Centaur (Bayer Diagnostics, Tarrytown, NJ). The intra- and 
interassay coefficients of variation for plasma glucose and serum insulin 
concentrations were 0.6 and 2.5%, and 4.5 and 12.2%, respectively. 
 
Blood lipids were analyzed using the Roche Modular autoanalyzer (Penzberg, 
Germany). Enzymatic colorimetric assays were used to analyze total cholesterol, 
triglyceride, and HDL cholesterol concentrations. The LDL cholesterol 











Serum concentrations of leptin (Linco Research, St Charles, Missouri, USA), high 
molecular weight (HMW) adiponectin (Linco Research, St Charles, Missouri, USA), 
high sensitive C-reactive protein (hsCRP, Immun Diagnostik AG, Bensheim, 
Germany) and IL-18 (BioSource Europe S.A., Nivelles, Belgium) were all analyzed 




2.4 Fat harvest technique 
 
On a separate day and after a 4 hour fast, fat biopsies were obtained from the 
abdominal DSAT, SSAT and gluteal areas, using a mini-liposuction technique. After 
local anaesthesia with Lignocaine hydrochloride (2%, Intramed, Port Elizabeth, 
South Africa), a small incision was made directly above the umbilicus. 200-300 ml 
of normal saline with adrenaline (0.1%, Intramed, Port Elizabeth, South Africa) 
and Lignocaine (0.75%, Intramed, Port Elizabeth, South Africa) was infused using 
an infiltration cannula (Lamis 14ga x 15cm, Byron Medical Inc., Tucson, AZ). An 
aspiration cannula (Coleman, 12ga x 15cm, Byron Medical Inc, Tucson, AZ) 
attached to a 10ml syringe was used to aspirate fat from above (SSAT) and below 
(DSAT) the fascia superficialis, under ultrasound guidance by a radiologist. Gluteal 
samples were obtained from the right upper quadrant using the same procedure. 
Approximately 2 ml of fat was extracted from each site and washed three times 
with normal saline or until no blood was visible. AT was then placed into vials and 




2.5 Quantification of mRNA by real-time quantitative PCR 
Total RNA was extracted from snap-frozen tissue samples using the Qiagen 
RNeasy system, and 500ng reverse transcribed into cDNA with random primers 
using the QuantiTect DNase/reverse transcription kit (Qiagen Ltd, Crawley, UK).  
cDNA (equivalent to 1ng total RNA) was incubated in triplicate in 1x Roche 
LightCycler®480 Probes master mix (Roche Diagnostics Ltd, Burgess Hill, UK) 
with gene specific primers (Invitrogen Ltd, Paisley, UK). A standard curve was 
constructed for each primer probe set using a serial dilution of cDNA pooled from 
all samples.  The NormFinder algorithm identified a combination of PPIA, 18S and 
RPLPO as the best normalization gene set, with expression levels not being altered 
by obesity, ethnicity or depot.  Results are presented as the ratio of abundance of 





Results are presented as means ± standard error. Two-way analysis of covariance 
adjusting for age, was used to compare anthropometric and metabolic measures 
between normal-weight and obese, black and white women, with Bonferroni 
posthoc analyses. Ethnic differences in abdominal adipose tissue depots were also 
adjusted for total fat mass. Data were normalized by log transformation, if 
required. Pearson correlation coefficients were used to explore the relationships 












Differences in mRNA levels between ethnicity and BMI groups within each SAT 
depot were analysed using two-way ANOVA, adjusting for age, with Bonferroni 
posthoc analysis. Repeated measures ANOVA, with Tukey posthoc analysis, was 
used to determine depot differences in gene expression. Partial correlations, 
adjusting for age and fat mass, were used to explore the associations between 
gene expression and measures of insulin sensitivity in both black and white 






The obese women were significantly older than the normal weight women (mean 
of 29 years vs. 25 years) (Table 2). Consequently, all subsequent analyses were 
adjusted for age.  
 
4.1 Body composition  
 
By design, all measures of body composition and regional fat deposition were 
significantly greater in the obese than the normal-weight women (Table 2).  
The lean and the obese black and white groups were well matched for BMI and 
total adiposity (dual-energy X-ray absorptiometry derived fat mass and % body 
fat).  
In normal-weight subjects, there were no significant ethnic differences in VAT or 
total SAT areas.  However, obese black women had significantly greater SSAT 
(325.1 ± 14.8 vs. 247.3 ± 15.4 cm2, p < 0.01) and significantly less VAT (98.4 ±11.3 
vs. 147.2 ± 11.8, cm2, p < 0.05) compared to obese white women. No significant 
ethnic differences in deep SAT were observed (269.9 ± 14.3 vs. 247.9 ± 14.3, p = 
0.92). Obese black women also had significantly greater gynoid fat than obese 
white women when adjusted for age and total fat mass (4.09 ± 0.18 vs. 3.54 ± 0.2 
kg, respectively, p = 0.043).   
 
4.2 Blood pressure  
 
None of the women were hypertensive, but obese women had significantly higher 
diastolic blood pressures compared to the lean group (p < 0.01) (table 2). There 
were no ethnic differences in either systolic or diastolic pressures. 
 
4.3 Insulin sensitivity and associations abdominal fat depots  
 
Fasting glucose levels did not differ between ethnic and BMI groups (Table 3) and 
all subjects had normal glucose tolerance according to American Diabetes 
Association Criteria (43).  
The obese groups had a significantly greater fasting serum insulin concentration 
(p < 0.01) and correspondingly lower IS (p < 0.01) than the lean groups (table 3).  
Interestingly, both the lean and the obese black women had significantly lower IS 
(p < 0.01) than their white counterparts (Table 3).  
 
In both black and white women (figure 1), DSAT (whites R = -0.55, p < 0.01, blacks 
R = -0.59, p < 0.01) and SSAT (whites R = -0.55, p < 0.01, blacks R = -0.50, p = 0.01) 
were significantly negatively correlated with IS. In contrast, VAT was significantly 
negatively correlated with IS in white but not black women (white R = -0.53, p < 
0.01, black R = -0.31, p = 0.13). In addition, gynoid (gluteal) fat mass was 










0.28, p = 0.22) (table 4). In contrast, hip circumference was positively associated 
with IS in white women (R = 0.45, p = 0.044) and not black women (R = -0.01, p = 
0.96). There were no significant associations between leg fat mass and IS in either 
ethnic groups.  
 
4.4 Lipids  
 
Obese white women had higher total cholesterol (p < 0.01), HDL cholesterol (p < 
0.01) and TAG (p < 0.01) compared to obese black women. There was no 




4.5.1 Circulating levels 
  
There were no significant ethnic differences in the levels of circulating 
adiponectin, leptin, hsCRP or IL-18, after adjusting for age (table 3). However, 
adiponectin levels were lower (p < 0.01), while leptin (p < 0.01) and hsCRP (p < 
0.01) levels were higher in the obese compared to lean subjects. Plasma IL-18 did 
not differ in lean vs. obese groups after correction for age (table 3).  
 
Circulating adiponectin (r = 0.49, p = 0.045), leptin (r = -0.62, p = 0.007) and 
hsCRP (r = -0.59, p = 0.002) levels were significantly associated with IS in white 
but not black women (adiponectin: r = 0.03, p = 0.86; leptin: r = -0.15, p = 0.44; 
CRP: r = -0.17, p = 0.35).  
 
4.5.2. Tissue mRNA levels 
 
Leptin mRNA levels correlated significantly with circulating leptin levels in all fat 
depots (DSAT: r = 0.72, p < 0.001; SSAT: r = 0.73, p < 0.001; Gluteal: r = 0.61, p < 
0.001). Similarly, adiponectin mRNA levels correlated significantly with 
circulating adiponectin levels in all fat depots (DSAT: r = 0.56, p < 0.001; SSAT: r = 
0.63, p < 0.001; Gluteal depot in blacks: r = 0.72, p < 0.001) except the gluteal depot 
of whites (r = 0.26, p = 0.196). 
In contrast, IL-18 mRNA levels did not correlate with circulating levels (data not 
shown). 
 
With obesity, adiponectin mRNA levels decreased significantly while leptin and IL-
18 mRNA levels increased significantly in all fat depots (SSAT, DSAT and gluteal; p 
< 0.001). Only leptin mRNA levels showed a significant ethnic difference (after 
being adjusted for age) being higher in black women in all three depots (p < 
0.001) (figure 3).  
 
Leptin and IL-18 mRNA levels, were higher in the gluteal than in either DSAT or 
SSAT depots (p < 0.001), whereas gluteal adiponectin mRNA levels were lower in 
the gluteal than the DSAT or SSAT depots (p < 0.001) in both ethnic groups. 
 
4.5.3 Tissue mRNA levels and associations with IS 
 
After adjusting for age and fat mass, only gluteal adiponectin mRNA levels (r = 
0.44, p  = 0.03) in black women were associated with IS. In white women, IS was 
associated with SSAT leptin mRNA levels (r = -0.54, p = 0.01) and IL-18 mRNA 















With the realization that adipose tissue is metabolically active, the hypothesis that 
the benefits of liposuction may go beyond aesthetics and the patient’s self-esteem 
began to be tested (44). Several prospective clinical trials (table 1) have examined 
the effects of LVL on IS, dyslipidaemia, and the inflammatory and adipokine 
profiles, but the results of these trials are conflicting. Although the clinical status 
of the patients, technique of IS measurement, volume of fat aspirated, changes in 
diet or exercise regimes, and duration of follow-up may account for the variable 
outcomes of these trials, our study has highlighted several other important 
factors.  
 
We have examined the ethnic specific variations in the distribution of adipose 
tissue and the associations between these fat depots and IR and CV risk factors. In 
this regard, we have found that obese black women were more IR, but 
accumulated more SSAT compared to obese white women who accumulated more 
VAT. Further, VAT in white women was associated with decreasing IS but not in 
black women. Rather, SAT, both deep and superficial SAT depots, were associated 
with decreasing IS in both black and white women. These findings are supported 
by Lovejoy et al (32) who found that African American women collect more SAT 
and less VAT than Caucasian women, and that SAT and not VAT was associated 
with decreased IS in African American women. 
 
In addition, we found that obese black women accumulate significantly more 
gynoid or gluteal fat than white women. Several cross sectional population studies 
have described gluteofemoral fat (as measured by thigh circumference, hip 
circumference and DXA determined thigh adipose tissue mass) as exerting specific 
functional properties that are associated with an improved metabolic and CV risk 
profile (45-48). Lemieux suggests that this protective effect may be as a result of 
peripheral fat having high lipoprotein lipase activity and low fatty acid turnover, 
thereby acting as a “metabolic sink” for the accumulation of excessive plasma 
lipids (49).   
Many of these cross sectional studies were however, performed in European 
countries were the relative proportion of black patients may have been small. In 
contrast, a recent study by Bays et al, in a mixed ethnicity patient cohort, has 
shown an increased risk of type 2 diabetes with an increase in the hip 
circumference (50). 
 
To the best of my knowledge, no studies have compared ethnic differences in the 
association of gluteofemoral fat and IR. Notably, a novel finding of our study was 
that the gluteal fat depot was associated with decreasing IS in black women, but 
not white women. On the contrary, an increase in the hip circumference in white 
women was associated with improved IS (i.e. a protective profile).  
This may be explained by their different adipocytokine expression profiles, with 
higher IL-18 and leptin mRNA levels in black compared to white women, 
particularly in the gluteal depot. The increased secretion of leptin in obesity is 
associated with decreased insulin sensitivity (4, 51) and hypertension (50, 52). 
Elevated IL-18 on the other hand, is pro-atherogenic (53) and is also associated 
with myocardial dysfunction (54) and the development of IR, independent of 










women, and IL-18 mRNA levels and SSAT leptin mRNA levels in white women, 
were associated with IS.  
 
There are several limitations to our study. Firstly, the number of participants, in 
each ethnic group and weight category, was relatively small. Also, they were not 
randomly selected and our cohort may therefore not be representative of the 
entire population. Similarly, we have only measured a few adipocytokines 
although numerous other important adipocytokines have been described. In 
addition, the gynoid area of interest was measured using the standard DXA 






In conclusion, we have found that black women are more IR than their white 
counterparts. In addition, obese black women accumulate more SSAT and less 
VAT than obese white women. VAT in white women was associated with 
decreasing IS but not in black women. However, SSAT and DSAT were negatively 
associated with IS in both ethnic groups. Based on these findings, we propose that 
a reduction in the volume of abdominal SAT (either SSAT or DSAT) by LVL, may 
improve IS in both ethnic groups. As obese black women accumulate more SSAT 
(and therefore SAT) however, they may benefit more than obese white women.  
Further, we have found that the gluteal area has the highest levels of 
adipocytokine mRNA in both white and black women, but it has variable ethnic 
associations with IS. In this regard, liposuction of the gluteal area may improve the 
metabolic profile in black women, but may worsen the IR in white women.  
 
We recommend that future prospective trials examining the metabolic effects of 












































Age (yrs) 23 ± 2 25 ± 2 28 ± 2 32 ± 2 
BMI (kg/m2) 22.9 ± 1.0C 22.6 ± 1.0D 37.9 ± 1.0C 36.5 ± 1.0D 
Fat mass (kg) 17.2 ± 1.9C 18.9 ± 2.0D 43.6 ± 1.9C 45.6 ± 2.0D 
Body fat (%) 30.4 ± 1.3C 29.4 ± 1.4D 47.2 ± 1.3C 45.3 ± 1.4D 
Regional body fat distribution 
Waist (cm) 76.2 ± 2.8C 79.7 ± 2.9D 113.0 ± 2.8C 108.3 ± 2.9D 
Hip (cm) 98.4 ± 2.4C 102.0 ± 2.4D 126.1 ± 2.4C 125.3 ± 2.4D 
WHR 0.78 ± 0.02C 0.78 ± 0.02D 0.90 ± .02C 0.86 ± 0.02D 
VAT (cm2) 60.4 ± 10.9C 56.7 ± 10.9D 98.4 ± 11.3b,C 147.2 ±11.8b,D 
Deep SAT (cm2) 68.0 ± 14.5C 83.3 ± 14.5D 264.6 ± 15.1C 257.6 ± 15.8D 
Superficial SAT (cm2) 98.0 ± 14.2C 95.2 ± 14.2D 325.1 ±14.8B,C 247.3 ±15.4B,D 
Total SAT (cm2) 176.7 ± 22.3C 175.5 ± 20.7D 591.3 ± 21.4b,c 492.2 ±21.4b,d 
Gynoid fat (kg) 1.76 ± 0.18C 1.70 ± 0.18D 4.09 ± 0.18C 3.54 ± 0.20D 
Blood Pressure     
Systolic (mmHg) 104 ± 4 110 ± 4 110 ± 4 112 ± 4 
Diastolic (mmHg) 69 ± 2C 70 ± 2D 77 ± 2C 76 ± 2D 
Values are unadjusted mean ± SEM. All P values adjusted for age. 
a P <  0.05 and A P < 0.01: Lean black vs. Lean white. 
b P <  0.05 and B P < 0.01: Obese black vs. obese white. 
c P <  0.05 and C P < 0.01: Lean vs. obese black. 
































Glucose tolerance and insulin sensitivity 
Fasting glucose (mmol/l) 4.4 ± 0.1 4.3 ± 0.1 4.6 ± 0.1 4.6 ± 0.1 
Fasting insulin (mU/l) 8.2 ± 1.3C 4.2 ± 1.3 14.9 ± 1.3B,C 8.7 ± 1.3B 
IS (x10-4 min/ U/ml) 2.8 ± 0.5A,C 6.1 ± 0.5A,D 1.8 ± 0.5B,C 3.8 ± 0.5B,D 
Lipid profile     
FFA (mmol/l) 0.36 ± 0.04 0.35 ± 0.04 0.40 ± 0.04 0.46 ± 0.04 
Triglycerides (mmol/l) 0.61 ± 0.08 a 0.82 ± 0.09a  0.82 ± 0.08B 0.90 ± 0.09B 
Total cholesterol (mmol/l) 3.6 ± 0.3 4.1 ± 0.3 d  3.8 ± 0.3B 5.0 ± 0.3b, d 
HDL-cholesterol (mmol/l) 1.3 ± 0.1A 1.8 ± 0.1A 1.1 ± 0.1b 1.6 ± 0.1b 
LDL-cholesterol (mmol/l) 2.0 ± 0.2 1.9 ± 0.3d 2.3 ± 0.2 2.9 ± 0.3d 
Circulating Adipokines     
Adiponectin (ng/ml) 6.6 ± 0.7c 6.8 ± 0.7d 3.8 ± 0.7C 4.1 ± 0.7D 
Leptin (ng/ml) 15.3 ± 3.3C 18.8 ± 3.4D 57.7 ± 3.3C 50.9 ± 3.4D 
hsCRP ( g/ml) 2.8 ± 0.8c 1.4 ± 0.8D 6.1 ± 0.8c 6.4 ± 0.8D 
IL-18 (pg/ml)  167.3 ± 44.8 170.7 ± 20.0 174.5 ± 37.8 279.6 ± 28.6 
Values are unadjusted mean ± SEM. All P values adjusted for age. 
a P <  0.05 and A P < 0.01: Lean black vs. Lean white. 
b P <  0.05 and B P < 0.01: Obese black vs. obese white. 
c P <  0.05 and C P < 0.01: Lean vs. obese black. 
d P <  0.05 and D P < 0.01: Lean vs. obese white. 
 























Figure 3. Expression of adiponectin, leptin and interleukin 18 in abdominal deep  
(DSAT) and superficial subcutaneous (SSAT) and gluteal (GLUT) adipose tissue depots 
in normal weight and obese black and white women. normal weight black;  
normal weight white;  obese black;  obese white. Bars represent means ± SE. * 
P<0.01, black vs. white; λ P<0.05, obese vs. normal weight; # P<0.05, Gluteal vs. DSAT 
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INSULIN SECRETION IN RELATION TO INSULIN SENSITIVITY AND THE ASSOCIATION 




More than three-quarters (77%) of the 40.5 million people living in South Africa are black African, of 
which more than 40% are urbanised.  Black African women living in urban areas are more often 
overweight or obese than urban black males or white females.  It was previously thought that obesity 
in black South African women was “healthy” and not associated with any diseases.  However, 
although black South African women rarely develop heart disease, they often develop diabetes 
(sugar disease) or high blood pressure.  
 
Previous studies done by Wits University have shown that some overweight black South African 
women don’t produce enough insulin, which is the hormone (natural chemical messenger) released 
from the body that helps to move glucose into the cells of the body.  In addition, they showed that 
even if these women do produce insulin, the cells in their body are not able to make use of it easily.  
In this study we will investigate these findings more thoroughly.  
 
The research group at Wits University also found that black women have less fat around their 
stomachs, but more fat around their thighs and the lower part of their bodies than white women.  Fat 
situated around the stomach is strongly associated with changes in stress hormones and diseases 
such as sugar disease, high blood pressure and heart disease.  Therefore, it is surprising that black 
women suffer from these diseases.  We would therefore like to investigate whether the fat that is 
situated deep in the lower part of the body may be as “unhealthy” as the fat situated around the 
stomach and may increase the chance of overweight or obese black South African women 
developing sugar disease and high blood pressure.  
 
It was always thought that fat situated around the body was just used for storage purposes.  
However, researchers have recently discovered that fat cells also produce natural chemical 
messengers (hormones) and other proteins that affect the functioning of the body.  In this study, we 
will investigate whether the hormones and proteins are different in the different fat stores (upper and 
lower body) of black and white women and whether these differences may explain the diseases that 
they develop.  
 
Therefore, the aim of the study is to test whether the body fat distribution of black women is in fact 
the factor that increases their chances of developing sugar disease and high blood pressure.  
 
Who can participate? 
 
Sixty black and white South African women between the ages of ~20 and 45 years, who are living in 
urban areas, will be recruited for the study.  Only women that are classified as lean (BMI > 19 and < 
25 kg/m
2
) or obese (BMI > 30 kg/m
2
) will be included in the study.  Subjects will be excluded from the 
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any endocrine abnormality (e.g. sugar disease, thyroid problems) or taking other medications, such 
as oral corticosteroids, and anti-hypertensive medications; iii) currently pregnant or breastfeeding; iv) 




You will receive the final results of the study as well as your individual results, including, body 
composition (weight, height, body fatness, muscle mass, body fat distribution), dietary intake, risk of 
diabetes, an estimate of your insulin sensitivity and secretion, blood lipids and blood pressure.  The 
results obtained from the fat biopsies will also be provided.  In addition, you will be paid a nominal 
sum of money for transport and the inconvenience to you.  
 
The findings of this research can be used to highlight specific areas for intervention in terms of drug 
therapy, for the treatment and management of the diseases associated with obesity in South African 
women.   
 
Procedures and potential risks: 
 
You will be required to complete approximately 3-4 sessions of testing, which will include the 
following tests:  
Transport (or money for transport) to and from testing will be provided. 
 
Session 1: Early morning before breakfast for approximately 4 hrs (this testing session can be 
divided in 2 parts)  
 
You will be requested to come to the laboratory at the Sports Science Institute in the morning after 
an overnight fast (10-12 hrs).  In other words, you must not eat or drink anything, except water for at 
least 10 hours.  You will be required to undergo the following tests/measurements: 
 
1) Information and consent: 
The purpose and procedures, as well as the risks and benefits of the trial will be explained to 
you. You will be given the opportunity to ask any questions, which will be answered by the 
investigator or the doctor involved in the study.  If you agree to participate in the study, you 
will sign the informed consent form and be entered into the trial.  
 
2) Demographic and lifestyle questionnaire: 
A demographic questionnaire will be administered and will include measures of socio-
economic status (on the basis of factors such as; asset index, education, housing and 
housing density, occupation), as well as questions related to family history, personal health, 
reproductive history, parity, dietary intake and physical activity and health habits. 
 
3) Blood pressure measurement:  
Blood pressure will be measured 3 times after you have rested for at least 20 min.   
 
4) Fasting blood sample and oral glucose tolerance test: 
A small plastic tube will be placed into a vein in your arm and a small tap attached from which 
blood samples (1 teaspoon – 5 ml) will be drawn at 30 min intervals during the 2 hr test.  
First, a fasting blood sample will be drawn from your arm for the measurement of blood lipids, 
glucose and various hormones. You will then be asked to drink a cup of water containing 75 g 
of glucose.  Blood glucose, insulin and free fatty acid concentrations will be measured from 
the blood samples taken before and 30, 60, 90 and 120 min after ingesting the glucose 
solution.  There are no appreciable risks for this test, other than those associated with routine 
blood sampling.  All procedures will be supervised and carried out by appropriately trained 
medical personnel using sterile techniques to minimise any risks of infection.  This test is 
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5) Body composition:  
Basic body composition measurements will be taken, including weight, height, waist and hip 
circumference.  In addition, you will undergo a dual-photon x-ray absorptiometry (DEXA) 
scan, which will accurately measure your fat and muscle mass, as well as your bone density.  
The radiation exposure with a DEXA scan is 11.3 microSieverts, which is significantly less 
than the radiation absorbed by a passenger on a return transcontinetnal flight (60 
microSieverts).  The scan will take approximately 20 minutes to perform.  
 
6) Body fat distribution and liver fat content: - N1 City Medi-Clinic 
You will be required to travel to N1-City Medi-Clinic where you will undergo magnetic 
resonance imaging (MRI scan) and computerised tomography (CT scan) in the 
radiology department.  The CT scan will be used to measure your body fat distribution, 
in other words, where the fat is situated around your belly.  The exposure to ionising 
radiation with the CT scan is less than 10 % of the total allowable occupational 
exposure per year (about 500 millirems out of 5000 millirems).  The MRI scan will be 
used to measure the fat content of your liver. MRI uses magnetism and radio waves, 
and will be used to generate a picture of your abdomen and your liver.  You will be 
required to lie on a bed, which is moved into a wide-bore tubular structure.  This is 
open at both ends.  You will be required to lie still for 15 minutes while being in 
constant voice contact with the Radiographer.  You will not experience any pain or 
discomfort and there are no risks associated with the scan.  However, you may 
experience slight claustrophobia during the scan.  
 
Session 2: Early morning before breakfast for approximately 4.5 hrs 
 
Insulin secretion and insulin sensitivity: 
 
You will be requested to come to the laboratory at the Sports Science Institute in the morning after 
an overnight fast (10-12 hrs).  In other words, you must not eat or drink anything, except water for at 
least 10 hours.  A small plastic tube will be placed into a vein in each arm.  You will then be required 
to undergo a test that will measure how much insulin your body produces and how sensitive your 
body is to insulin.  We will inject a concentrated glucose solution (~ 30-100 ml, depending on your 
weight) into one vein over a 1-minute period. Small amounts of blood (1 teaspoon) will be withdrawn 
from the other arm at regular intervals (1-2 minutes) for 20 min.  After 20 min, insulin will be infused 
into your arm, which will assist your body take up the glucose into the cells.  Further blood samples 
(1 teaspoon each) will be drawn from your other arm for a further 3.5 hrs.  During this test, a 
maximum of 200 ml of blood will be drawn (1/3
rd
 of the amount drawn when you donate blood).  
During the tests, you will be required to sit or lie quietly and videos will be provided for entertainment.  
There are no appreciable risks for this test, other than those associated with routine blood sampling.  
All procedures will be supervised and carried out by a medical doctor and appropriately trained 
medical personnel using sterile techniques to minimise any risks of infection.  These tests are used 
routinely in research to accurately determine insulin secretion and insulin sensitivity.  This test should 
be undertaken at the follicular phase of your menstrual cycle i.e. within 10 days of starting 
menstruation. 
 




You will be requested to undergo fat biopsies from the stomach and buttocks areas.  The fat 
samples will be used to analyse the proteins and hormones produced by the fat cells, which may 
explain why black and white South African women get certain diseases.  You will be required to 
come to the laboratory the Sports Science institute in the morning after an overnight fast (10-12 hrs).  
In other words, you must not eat or drink anything, except water for at least 10 hours.  A medical 
doctor will perform the fat biopsies with the assistance of a radiographer at the Sports Science 
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inform us if you have had any previous reactions to any other anaesthetics, for example at the 
dentist.  After the anaesthetic has taken effect, small incision (0.5-1 cm) will then be made in the skin 
and fat samples (1.5 cm
3
) will be removed using a needle connected to a syringe.  After this 
procedure, a waterproof sterile dressing will be applied.  You may develop bruising and some 




Participation in this research study is absolutely voluntary.  You do not have to take part if you do not 
want to.  You may withdraw at any time without stating a reason and without prejudice.  The doctor 
or researcher can also withdraw you from the study.  You will be provided with all your individual 
results, as well as a summary of the trial results on completion of the study.   
 
Strict confidentiality of results will be maintained.  All records will be kept in a locked room and in a 
secure computer database in the research unit.  Your name will not be used in any publication of the 
results.   
 
The University of Cape Town and its team of researchers, who are working under the mandate of the 
University, will be responsible for treating any adverse or untoward events arising from participation 
in this research study.  Trained medical professionals will perform all medical or invasive procedures, 
under sterile conditions.  
 
 
Thank you for your participation.  Please contact me immediately if you would like to ask any 
questions or you experience any problems during or after the tests. 
 
Dr Julia Goedecke (PhD)    
UCT/MRC Research Unit for Exercise Science and Sports Medicine 
3
rd










Dr Joel Dave      Ms Madelaine Carstens  
Endocrine Unit     Research dietician and subject Liaison 
Department of Medicine     2
nd
 Floor SSISA 
Groote Schuur Hospital    Tel: 650-4568  0848557339 (Cell) 
Cape Town      mcarstens@sports.uct.ac.za 
 
Tel:  0824111111 
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“I, _________________________, hereby give consent to participate in this research trial to be 
conducted by the UCT/MRC Research Unit for Exercise Science and Sports Medicine, within the 
Department of Human Biology at the University of Cape Town.  I understand that I will undergo 
testing at the Sports Science Institute, which will include completion of a demographic and lifestyle 
questionnaire, the measurement of blood pressure, body composition including DEXA, CT and MRI 
scans, blood lipid and hormone levels, oral glucose tolerance, as well as insulin secretion and 
sensitivity.  I also understand that fat samples (~1.5 cm
3
) will be taken from the fat stores in my 
abdominal (stomach) and gluteal (bottom) areas.  I have read and have had explained to me the 
procedures described above.  I have had an opportunity to ask questions.  My questions have been 
answered in a satisfactory way.  I understand the nature of the trial and the risks and benefits 
associated with my participation.  I understand that I am free to withdraw from this study at any time.  
 
 
Name: __________________      Signature: ________________     Date: __________ 
 
 
Witness: ___________________      Signature ________________ 
 
